A patient calls five days after delivery. She says she’s bleeding and wants to know if it’s normal.

“How much are you bleeding?” I ask.

“A lot, I think?”

“Are you soaking through a pad in an hour? How many pads are you using in a day?”

Long pause. “I haven’t really been counting.”

Postpartum is chaos. You’re exhausted, overwhelmed, and completely focused on keeping a tiny human alive. Your own body becomes an afterthought. But the weeks after birth are a vulnerable time. Things can go wrong—sometimes quickly. Knowing your numbers helps you tell the difference between normal recovery and something that needs attention.

Interactive Postpartum Warning Signs Guide

Your Body Just Did Something Enormous. It Needs Monitoring Too.

Pregnancy gets nine months of careful tracking. Prenatal visits, ultrasounds, blood tests, kick counts. Then the baby comes out and suddenly all that attention shifts to the newborn. You’re handed a baby and sent home with instructions for infant care—but often very little guidance about what to expect for yourself.

Here’s the truth: your body doesn’t reset the moment you deliver. Blood pressure issues can develop or worsen after birth. Bleeding can become dangerous. Infections can set in. Mood disorders can emerge. These aren’t rare complications—they’re common enough that every postpartum person should know the warning signs.

The problem is that postpartum symptoms are easy to dismiss. You’re supposed to be tired. You’re supposed to be uncomfortable. You’re supposed to bleed. So how do you know when “supposed to” becomes “something’s wrong”?

Numbers help.

The rest of this post is for paid subscribers.

Read more

Two alien observers visited earth to learn how humans reproduce. They found moms.gov and concluded the male is not biologically involved. They were not entirely wrong about the policy.

 The following is a field report filed by two observers from the Galactic Census Bureau, assigned to document human reproductive biology for the 2025 intergalactic population survey. Their methodology was rigorous. They consulted only official government sources. This is what they found.

Day One: The Official Resource

The observers began where any responsible researcher begins: with the government. The United States of America maintains a website called moms.gov, operated by its Department of Health and Human Services and launched, with considerable ceremony, on the holiday this species has designated for honoring its maternal units.

Subscribe

The observers spent several hours with this resource. They took detailed notes.

According to moms.gov, human reproduction requires the following: a female who tracks her basal body temperature each morning before speaking or moving;

a female who monitors changes in her cervical secretions across a 28-to-35-day cycle;

a female who charts this data across eight to twelve months to establish her personal fertile window;

a female who takes 400 micrograms of folic acid daily;

a female who avoids alcohol, maintains a healthy weight, and manages stress.

The observers reviewed these instructions carefully. They cross-referenced them with their training in basic xenobiology.

Something appeared to be missing.

They searched the resource for any mention of the male of the species. They found references to the male in the context of emotional support during pregnancy. They did not find the male in the context of conception. The word sperm does not appear on moms.gov's fertility guidance pages. The word semen does not appear. The phrase male factor does not appear.

Observer One filed the following preliminary note: "Human reproduction may be parthenogenic. Recommend further investigation before filing census report."

Day Two: The Fertilization President

The observers were thorough. They did not stop at one source.

Further research revealed that the leader of this nation had, in February 2025, signed an executive order to expand access to a procedure called in vitro fertilization, or IVF. He had referred to himself, in public, as the "fertilization president." The observers noted this title with interest. They hoped it would clarify the male's role.

In October 2025, the fertilization president announced a landmark agreement with a pharmaceutical company called EMD Serono. The agreement would reduce the cost of three injectable medications — Gonal-F, Ovidrel, and Cetrotide — by 84% through a government platform called TrumpRx.gov. The president stood in his Oval Office. Officials stood beside him. The announcement was covered extensively.

The observers examined all three medications. Gonal-F stimulates the female's ovaries to produce multiple eggs. Ovidrel triggers the final maturation of those eggs. Cetrotide prevents premature ovulation.

All three act exclusively on the female reproductive system.

The observers searched the TrumpRx platform for any medication addressing male reproductive function. They found none. They searched the executive order for any mention of sperm. They found none. They searched the associated press releases, the White House fact sheet, and the Labor Department guidance on employer fertility benefits.

Observer Two updated the preliminary note: "Fertilization president appears to be fertilization-adjacent. The male's biological contribution remains unlocated in official documentation."

— — — PAYWALL BREAK — — —

Day Three: The $300 Question

On the third day, one of the observers made a discovery.

Buried in the National Library of Medicine's database — not on moms.gov, not on TrumpRx.gov, not in the executive order, not in any document carrying a .gov domain that addressed fertility directly — was a description of a diagnostic test called a semen analysis.

The observers read it carefully.

A semen analysis evaluates the male's reproductive contribution: sperm count, with a normal threshold of at least 15 million per milliliter; motility, with at least 40% of sperm required to move effectively; and morphology, with at least 4% required to be normally shaped. The test is non-invasive. It is conducted in a clinical laboratory. Results are typically returned within 24 to 48 hours. The cost, in the United States, is approximately $200 to $300.

The observers then consulted the peer-reviewed literature. They found that male factor is solely responsible for infertility in approximately 20% of couples and contributes to the problem in an additional 30% to 40%.(1,2) In total, male factor substantially contributes to approximately 50% of all cases in which human couples cannot conceive.(3)

Observer One sat quietly for a moment.

"So," Observer One said, "for roughly half the couples who cannot reproduce, the answer may be findable with a $300 test that takes one appointment and requires no injections, no surgical procedures, and no ovarian stimulation."

"That appears to be correct," said Observer Two.

"And the government's response was to discount the ovarian stimulation drugs."

"Yes."

"The drugs that cost $5,000 per cycle. That represent approximately 20% of the total cost of a treatment that runs $15,000 to $20,000."

"Correct."

Observer One made a note. Then crossed it out. Then made it again.

Day Four: The Experts

The observers had not given up. They had found the science. They had found the policy. What they had not yet found was any medical authority who had, on the record, told the government that its fertility program was missing half the biology.

This seemed like an important question. A country in which human reproduction is the subject of national policy has, presumably, professional societies whose function is to advise that policy. The observers were optimistic.

The American College of Obstetricians and Gynecologists — the principal professional organization for the species’ reproductive specialists — maintains detailed guidance on infertility evaluation. The observers found it. It acknowledged, correctly, that a semen analysis should be part of any infertility workup. It noted that male factor is a significant contributor to infertility in couples seeking conception. It was, by the standards of the documentation reviewed thus far, complete.(4)

The observers then searched for any statement ACOG had issued about moms.gov. They searched for any public response to the government’s fertility initiative. They searched for any press release, letter, or formal communication noting that the national preconception website did not mention sperm.

They found nothing.

Then Observer One remembered something. There was a society whose sole professional focus is reproductive medicine — infertility, assisted reproduction, the entire clinical territory of human conception. The American Society for Reproductive Medicine. ASRM.

“This is it,” Observer One said. “If any organization on this planet would have noticed that the national fertility policy does not mention sperm, it would be the one that exists for no other reason.”

The observers found ASRM’s response to the government’s fertility initiative. It was enthusiastic. The society had praised the executive order on IVF access. It had welcomed the TrumpRx drug discount program. It had expressed gratitude for the administration’s attention to reproductive medicine. The press releases were warm. The quotes were complimentary.

The observers searched these statements for any mention of male factor. For any note that the drugs being discounted act exclusively on the female reproductive system. For any recommendation that a semen analysis precede ovarian stimulation in couples of unknown fertility status.

Nothing.

Observer Two stared at the screen. “The society whose entire reason for existing is infertility hailed a fertility initiative that ignores male factor.”

“Hailed it warmly,” Observer One confirmed. “With gratitude.”

“Without noting the omission.”

“Without noting the omission.”

They searched SMFM — the Society for Maternal-Fetal Medicine. Nothing directed at moms.gov. They searched the American Urological Association, whose members treat male infertility every day. Nothing. They searched RESOLVE, the national infertility patient advocacy organization, for any public statement about the omission of male factor from the government’s flagship fertility resource.

Nothing.

Observer Two, who had maintained composure through three days of increasingly confusing documentation, said: “Let me understand this. They know.”

“They know,” Observer One confirmed. “The knowledge exists. It is in the guidelines.”

“And the government launched a fertility resource for couples who want to conceive, and it does not mention half the relevant biology, and the professional societies that hold this knowledge —”

“No.”

“They said nothing.”

“Nothing that we could find.”

Observer Two looked at the field notes for a long time. “On our planet,” Observer Two said, “when an official document contains an error affecting half its intended beneficiaries, the professional bodies responsible for that subject area file a correction.”

“Yes,” said Observer One.

“We call it accountability.”

“I know.”

“They have a word for it here too, I believe.”

Observer One did not respond. Observer One was already writing in the field notes.

Preliminary finding, Day Four: The omission documented in Days One and Two is known to those in the best position to correct it. Whether this represents consensus, deference, institutional inertia, or political calculation falls outside the scope of this census survey. What is within scope: the gap between what the medical evidence says about male factor infertility and what official government fertility resources say about it is not an accident of ignorance. It has been seen. It has not been corrected.

The Filed Report

The observers submitted the following findings to the Galactic Census Bureau:

Human reproduction is a two-gamete process requiring both a female egg and a male sperm cell. This is not in dispute in the scientific literature. It appears, however, to be in dispute in American fertility policy.

The official government resource for preconception guidance addresses the female reproductive cycle in considerable detail. It does not address the male reproductive contribution. It promotes fertility awareness-based methods as a primary strategy for couples who cannot conceive. A fertility awareness method tracks the woman's ovulation. It does not evaluate sperm.

The national government has invested political capital in reducing the cost of medications that stimulate female ovarian function for IVF. IVF is an appropriate treatment for many causes of infertility. It is not the appropriate first step for a couple in which the male has a low sperm count, poor motility, or a varicocele — a surgically correctable condition present in up to 40% of men evaluated for male factor infertility, for which repair is often effective.(2) For these couples, IVF without a prior semen analysis is not a fertility treatment. It is an expensive procedure addressing the wrong partner.

We recommend that the species consider the following, in order: one semen analysis, before anything else. Its cost is $300. Its information content, for approximately half of infertile couples, is decisive.

We are returning to our home planet. We found the biology clear. The policy, less so.

The cervical mucus charts were especially confusing.

My Take

The satire is exact. Every number in this piece is real. Male factor contributes to 50% of infertility cases.(1,2,3) A semen analysis costs $200 to $300. The Trump administration's fertility initiative discounts drugs that act exclusively on the female reproductive system. moms.gov does not mention sperm. None of this is a caricature. It is the policy, described accurately, through a frame that makes its absurdity visible.

I am not dismissing the IVF cost initiative. Reducing the cost of fertility medications is a real benefit for real patients. For couples who need IVF — and many do — an 84% discount on stimulation drugs is meaningful. I do not minimize that.

What I am saying is that fertility policy which begins with the woman and ends with the woman, without pausing to evaluate the man, will send roughly half its intended beneficiaries in the wrong direction. Some of them will undergo months of ovarian stimulation, egg retrieval, and embryo transfer before anyone thinks to order a semen analysis. Some of them will spend $20,000 on a cycle before anyone asks whether the problem was a varicocele that a urologist could have repaired for a fraction of that cost.

The semen analysis is the single most important test in the infertility workup. It is cheap, non-invasive, fast, and informative. Its absence from every government fertility resource launched in the past 12 months is not an oversight. It reflects a persistent cultural assumption — one this country's fertility policy has apparently not examined — that infertility is a female problem.

It is not. It is a couple problem. Half the time, it is a male problem. The $300 test that establishes which half you are in should be the first thing any couple struggling to conceive is told to do. It should be on moms.gov. It should be in the executive order. It should be the first slide in any government presentation about helping Americans have babies.

The aliens were confused. They had good reason to be.

Subscribe

Bottom Line

A fertility policy that ignores male factor is not a fertility policy. It is a preconception program for women. Those are not the same thing, and couples who need to know the difference are currently being failed by every official resource their government has built.

If you want the complete picture of infertility — what causes it, how to evaluate it, and what the evidence says about when to seek help — ObGyn Intelligence covers it without the ideological filter. Subscribe below.

References

1. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13:37. doi: 10.1186/s12958-015-0032-1. PMID: 25928197.

2. Leslie SW, Siref LE, Khan MAB. Male Infertility. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 32965929.

3. Krausz C, Escamilla-Sanchez A. Male infertility. Lancet. 2021;397(10271):319-332. doi: 10.1016/S0140-6736(20)32667-2. PMID: [VERIFY].

4. American College of Obstetricians and Gynecologists. Evaluating Infertility [FAQ]. Washington (DC): ACOG; 2022. Available from: https://www.acog.org/womens-health/faqs/evaluating-infertility.

Share

The building is on the Upper East Side of Manhattan. The address appears on federal grant applications, on faculty appointments, on papers published in the American Journal of Obstetrics and Gynecology. The department chair holds an endowed professorship. The division chief sits on national guidelines committees. The attendings publish on maternal health disparities, on racial inequity in obstetric outcomes, on the obligation of academic medicine to serve underserved populations.

There are two ways to receive prenatal care in this building.

The first way: you call the faculty practice. You ask about your insurance. If you have Aetna PPO, or Cigna, or United commercial, or Oxford, an appointment is scheduled. You will see an attending physician. She knows your name before you sit down. She will be at your delivery.

The second way: you have Medicaid. You are directed to the resident clinic. You will receive care. It will be clinically supervised. The resident who examines you in week 12 will likely not be the resident who examines you in week 28. The attending supervising the clinic that day may not have supervised your previous visits. When you arrive in labor, the team that receives you will not know you.

These are not two philosophies of care. They are two systems of care, operating in the same building, serving populations that differ substantially by race and insurance status, and producing graduates who have been trained on patients their supervisors will not see in their own offices.

The Published Evidence

This two-tier structure is not an allegation. It is a documented phenomenon in the peer-reviewed literature.

A cross-sectional study examining primary care practices at academic health centers across the United States found that 78 percent of participating institutions maintained at least two clinics distinguishable by the proportion of patients with Medicaid insurance. Of those, 38 percent had clinics differing by 20 percentage points or more in Medicaid patient share, and 10 percent had clinics differing by 40 percentage points or more. The clinics with higher proportions of Medicaid patients were more likely to employ resident physicians as providers of longitudinal care and more likely to serve patients who were Black or Hispanic. Faculty physicians were significantly less likely to provide continuity of care in the high-Medicaid clinics.

The phenomenon operates not only at the clinic level but at the individual physician level within the same practice. A 2023 study published in JAMA Network Open, using 2017 claims data from approximately 134 million patients and 200,000 physicians, examined differences in patient panel demographics between senior and junior physicians in the same practices. The lead author, Michael Barnett of the Harvard T.H. Chan School of Public Health, described the finding as a widely known secret: senior physicians, who in an academic setting are also the researchers and the committee members and the named faculty, tend to see fewer Medicaid-insured patients and fewer racial and ethnic minority patients than junior physicians and residents in the same practice.

Barnett called this a two-tiered system by physician seniority that promotes racial and economic segregation. He was careful to note that it is far from clear that senior physicians provide higher-quality care than junior physicians in absolute terms. But to the extent that patients value continuity, experience, and personal relationships with their providers, the distribution of that access along racial and economic lines is a structural form of inequity regardless of absolute quality differences.

The Billing Mechanism Nobody Discusses

There is a dimension of this two-tier system that has received almost no attention in the health equity literature, and it involves the way obstetric care is billed.

Until January 2027, when a new CPT code structure takes effect, obstetric care in the United States is billed under a global package system. A single code covers all routine prenatal visits, the delivery itself, and postpartum care within six weeks of delivery. The global package is a bundled payment: the physician who delivers the baby collects a single fee that nominally encompasses the entire pregnancy.

This creates a specific and powerful financial incentive that shapes how Medicaid participation actually works in obstetric practice. An obstetrician can enroll in a state Medicaid program, appear in that program’s provider directory, be counted in access statistics as a participating Medicaid provider, and still provide essentially no prenatal care to Medicaid patients. She enrolls to capture delivery billing. The prenatal care, the routine visits, the relationship-building that defines pregnancy management, flows to the resident clinic. The delivery, which happens once, represents a discrete revenue event that the enrolled attending can capture without having managed the pregnancy at all.

This is not a hypothetical. It is the economic logic underlying a pattern that every obstetrician in a large academic medical center recognizes: Medicaid enrollment rates among OB/GYNs look reasonably healthy in national statistics, but those statistics conflate enrollment with participation in prenatal care. The two are not the same thing. A 2026 Health Affairs study found that more than one quarter of physicians enrolled in Medicaid did not treat a single Medicaid patient in the year studied. In obstetrics, the global billing structure provides the specific mechanism by which a physician can be enrolled and present for deliveries while absent for prenatal care.

The patient in this system has a Medicaid provider on paper. She does not have a doctor.

What the Prenatal Data Shows

The clinical consequences of this two-tier structure are measurable in the obstetric literature. A retrospective cohort study comparing prenatal care at a resident clinic versus an attending clinic within the same large midwestern healthcare system found that 63 percent of prenatal patients were served by the resident clinic. The two patient populations differed significantly by insurance status, race and ethnicity, partnership status, and age. Despite being scheduled for approximately the same number of prenatal appointments, resident clinic patients attended 1.13 fewer appointments than attending clinic patients, a statistically significant difference with meaningful clinical implications for continuity and outcome.

Among Black patients with public insurance, the attendance gap was particularly pronounced: they attended an average of 2.04 fewer appointments than white patients with public insurance at the same clinic. The study’s authors concluded that the resident care model, with its inherent discontinuities and care delivery challenges, may be underserving the patients who are most vulnerable to prenatal care non-adherence from the outset.

This finding points to a compounding effect. The patients routed to resident clinics by their insurance status are also the patients for whom continuity of care is most clinically important, because they tend to carry more risk factors, face more logistical barriers to attendance, and benefit most from a care relationship that does not require re-establishing context at every visit. The two-tier system concentrates discontinuity precisely where continuity matters most.

The Coming Billing Reform and Its Limits

ACOG has announced a significant restructuring of obstetric billing codes, effective January 1, 2027. The global package codes will be eliminated and replaced with unbundled evaluation and management codes billed per visit. ACOG anticipates this change will allow more comprehensive and tailored billing of prenatal services, including social needs screening, mental health visits, and telehealth encounters that the global package structure poorly accommodates.

This reform addresses a genuine problem. The global package is an artifact of a care model that assumed a single provider managing a single uncomplicated pregnancy, a model that has not reflected the reality of academic or even group practice obstetrics for decades. Unbundling the code will make prenatal care individually billable and will make the economics of prenatal care more transparent.

What it will not do, by itself, is change the reimbursement rate. An unbundled prenatal visit billed to Medicaid at 72 percent of the Medicare rate for an evaluation and management code is still a Medicaid visit at 72 percent of the Medicare rate. The faculty obstetrician who declined Medicaid patients under the global package will have the same financial incentive to decline them under the per-visit structure unless the underlying reimbursement changes. The mechanism of exclusion shifts; the economics that drive it do not.

The Institutional Contradiction

The most challenging aspect of this two-tier system is not its existence. It is its location. It operates inside the institutions that have simultaneously positioned themselves as the national leaders on maternal health equity. The same departments that hold NIH grants for research on racial disparities in obstetric outcomes are operating faculty practices that concentrate those disparities. The same attendings who are listed as investigators on health equity studies are the attendings whose private practices do not accept Medicaid.

This is not hypocrisy in the crude sense. It reflects a system in which individual physicians make economically rational decisions within a structure that produces collectively inequitable results, and in which institutions have not been required to reconcile those results with their stated commitments. Publishing on health equity is compatible, in the current environment, with operating a health-inequitable practice. No accreditation body, no NIH grant review, no journal editor has made those two things incompatible.

Until they are made incompatible, the two doors will remain.

My Take

I checked the faculty practice websites of the major academic obstetric programs in Manhattan. I looked for Medicaid on their insurance lists. It was not there. This is not a generalization. It is an observation. I checked each one.

I want to be precise about what this means and what it does not mean. It does not mean that the attendings at these institutions are bad physicians or that they do not care about their patients. It means that they are operating within a reimbursement structure that makes accepting Medicaid economically irrational for a private faculty practice in a high-overhead urban market, and that no institutional policy requires them to do otherwise.

The fix is not complicated at the level of mechanism. It is complicated at the level of institutional will. Require faculty practices at academic medical centers that receive federal research funding to accept Medicaid. Tie NIH funding eligibility to demonstrated equitable access across insurance types. Make the two-tier system visible by requiring public disclosure of insurance acceptance by practice type, not just by institution. Enforce the mission statement.

Academic medicine says it is committed to health equity. The faculty practice roster is an annual audit of whether that commitment is real. At most major academic obstetric programs in this country, that audit currently fails.

Coming Next Week — For Paid Subscribers

Post 4: The “Own Doctor” Problem. A Black woman on Medicaid in a large American city will see an average of four to six different providers across her prenatal visits. She arrives in labor as a stranger to the team that receives her. The care is clinically supervised. But nobody knows her. National data covering 922,000 pregnancies found that continuity of care reduces stillbirth rates specifically for Black women — the only demographic group in which the difference reached statistical significance. What does that mean for the rotating-provider model that Medicaid patients are routed into by default? What would it cost to fix? That post publishes next week.

Posts 4 through 10 are available to paid subscribers at obmd.com. An annual subscription is $60 per year, less than $1.20 per week. The series covers hospital quality stratification, maternity care deserts, the implicit bias training evidence, the April 2026 JAMA doula review, the postpartum coverage cliff, and the closing argument about who benefits from keeping the focus on attitudes rather than systems. If you have been reading ObGyn Intelligence and finding it useful, this is the series that makes the subscription worth it.

References

1. Mafi JN, Vangala M, Yazdany J, et al. Separate But Not Equal? A Cross-Sectional Study of Segregation by Payor Mix in Academic Primary Care Clinics. J Gen Intern Med. 2023;38(11):2537-2545.

2. Barnett ML, Olenski AR, Jena AB. Differences by Physician Seniority in Race and Ethnicity and Insurance Coverage of Treated Patients. JAMA Netw Open. 2023;6(12):e2347082.

3. Essien UR, He W, Ray A, et al. Disparities in Quality of Primary Care by Resident and Staff Physicians: Is There a Conflict Between Training and Equity? J Gen Intern Med. 2019;34(7):1184-1191.

4. Vanjani R, Pitts A, Aurora P. Dismantling Structural Racism in the Academic Residency Clinic. N Engl J Med. 2022;386(21):2054-2058.

5. Wallis CJD, Jerath A, Coburn N, et al. Association of Surgeon-Patient Sex Concordance With Postoperative Outcomes. JAMA Surg. 2022;157(2):146-156.

6. Vasan A, Flores LE, Adamson AS. Resident Versus Attending Prenatal Care Models: An Analysis of the Effects of Race and Insurance on Appointment Attendance. Matern Child Health J. 2023;27(8):1388-1396.

7. Dunn RA, Kaczynski L, et al. One-Quarter of Medicaid Doctors Do Not Actually Treat Medicaid Patients. Health Aff (Millwood). 2026;45(2). doi:10.1377/hlthaff.2025.01234.

8. ACOG. Payment for Obstetric Services. ACOG Practice Management; 2024. Available at: acog.org/practice-management/coding.

She is not being careless.

She is being human.

Two Nobel laureates spent their careers explaining exactly what happened in that room.

Herbert Simon won the Nobel Prize in Economics in 1978 for something that sounds simple but was genuinely radical: proving that human beings cannot make optimal decisions. Not because we are poorly trained, but because the cognitive task of evaluating all available information, weighting it correctly, and choosing the best option exceeds the architecture of the human brain. Simon called this bounded rationality. He coined the term satisficing — a blend of satisfy and suffice — to describe what the brain actually does: it scans a limited set of options, picks one that clears a good-enough threshold, and moves on.

Subscribe now

In a busy labor and delivery unit, a clinician who paused over every assessment to systematically evaluate all alternatives would be clinically useless.

The satisficing brain is the feature, not the bug, that keeps the floor running. Simon understood this. He was not condemning heuristic thinking. He was mapping its limits.

Daniel Kahneman won the Nobel Prize in Economics in 2002 for a related but sharper finding: the mental shortcuts we use are not just limited — they are systematically biased in predictable ways. Anchoring: the first diagnosis encountered shapes every judgment that follows. Availability bias: we overestimate outcomes we can easily recall from recent experience. Overconfidence: after a run of good outcomes, clinicians consistently underestimate risk in the next case. These are not random errors. They are structured, replicable, and invisible to the person making them.

This is not theoretical. The Society for Maternal-Fetal Medicine acknowledged in a 2022 Special Statement that clinical decision-making in obstetrics is routinely affected by cognitive biases that can lead to medical errors.(1)

The rest of this post is for paid subscribers.

Read more

Overall assessment

Moms.gov is an official HHS public-facing site for new and expecting mothers. Its stated purpose is to provide “resources, information, and help” for mothers and fathers facing difficult or unexpected pregnancies. The site includes some medically useful links, especially to FQHCs, breastfeeding resources, maternal mental health support, Head Start, CDC pregnancy resources, and substance-use information. It also links directly to OptionLine as the pregnancy-center locator, which is the site’s major ethical and evidence problem. Moms.gov states that pregnancy centers may offer pregnancy tests, ultrasounds, STI testing, parenting support, childbirth classes, referrals, and material goods, and it says there are more than 2,750 pregnancy centers nationally. It does not state with equal prominence that the linked OptionLine network does not provide or refer for abortion services.

Subscribe now

From an evidence-based public health perspective, the site is not uniformly unreliable, but it is not neutral. It’s Ideological. It combines legitimate health resources with ideologically selected pregnancy-support pathways. That matters because a federal site carries institutional authority. When HHS links pregnant women to a pregnancy-center network that excludes abortion referral, the limitation should be explicit, prominent, and visible before the user leaves the government site.

Page-by-page / section-by-section critique

Home page: “Resources, Information, and Help for New and Expecting Mothers”

The opening frame is supportive but selective. It emphasizes unexpected pregnancy, mothers, fathers, family wellbeing, and “American families.” That framing is not medically wrong, but it is value-laden rather than clinically neutral. A federal pregnancy resource page should clearly distinguish medical care, social support, religious or ideological counseling, and non-referring pregnancy centers. Moms.gov does not do this adequately.

“Access Pregnancy Support Services and Health Centers”

This is the most important section. It links users to OptionLine to “Find Pregnancy Centers Near You.” The problem is not that pregnancy centers exist. Many provide diapers, clothing, peer support, parenting classes, and emotional support. The problem is that the linked network states that its participating centers offer peer counseling and information but do not offer or refer for abortion services. That disclosure appears on the OptionLine locator page, not prominently on Moms.gov before the referral. For a government website, that is a serious transparency failure.

A clinically honest version would say: “Pregnancy centers may provide free support and limited services, but many do not provide comprehensive reproductive health care and may not provide or refer for abortion.”

Federally Qualified Health Centers

This section is much stronger. Moms.gov links to HRSA’s FQHC locator and correctly describes FQHCs as serving medically underserved areas and providing primary care, maternal care, and prenatal care regardless of ability to pay. That is appropriate public health routing. Unlike pregnancy centers, FQHCs are medical-care entities with defined federal standards, clinical staff, and accountability structures.

This section should be placed before the pregnancy-center locator, or at least presented as the primary route for medical care.

Nutrition quick facts

The basic nutrition advice is broadly reasonable: folic acid, nutrient-dense foods, iron-rich foods, folate-rich greens, legumes, eggs, dairy, and low-mercury omega-3 seafood. The CDC folic acid recommendation of 400 micrograms daily is consistent with standard public health guidance.

Share

The linked “Dietary Guidelines for Americans 2025–2030” document, however, has a strongly political and ideological tone. It uses phrases such as “Make America Healthy Again” and frames nutrition policy as a major political reset. That language is not ideal for a government clinical resource aimed at pregnant women. Nutrition advice should be evidence-based, practical, and nonpartisan.

“Jumpstart your child’s future with Trump Accounts”

This section is not a health resource. It is a financial-policy promotion embedded in a maternal health page. Even if the program is legal and available, its placement on a pregnancy health resource site blurs public health communication with political branding. It does not belong in a clinical or pregnancy-support information pathway.

“Looking to start a family?” / TrumpRx

This section links fertility-related medication access to TrumpRx. It includes a reasonable warning to talk with a qualified clinician before starting medications for weight management or fertility. But the section is clinically thin. Fertility evaluation requires more than medication pricing. It should address age, ovulatory function, semen analysis, tubal factors, endometriosis, PCOS, diabetes, obesity, thyroid disease, and timing of referral.

As written, it feels more like a promotional link than a complete preconception or infertility resource.

Preconception health

This is one of the better sections. It correctly states that addressing chronic disease and identifying risk factors can improve pregnancy outcomes. The reference to preconception health is appropriate. However, the section then highlights fertility awareness-based methods. FABMs can help some women identify fertile windows and cycle irregularities, but they are not a substitute for clinical evaluation when infertility, irregular menses, PCOS, endometriosis, recurrent pregnancy loss, diabetes, hypertension, or advanced reproductive age are present.

The section should be expanded to include folic acid, medication review, diabetes optimization, hypertension management, vaccination, substance use, genetic carrier screening when appropriate, and timing of referral.

Breastfeeding information

The breastfeeding section links to established federal resources and correctly states that breastfeeding has benefits but can be difficult. This is reasonable. The language “breastmilk is the perfect food” is common in public health messaging, but it can be emotionally loaded for women who cannot breastfeed, have low milk supply, need medication, have trauma, return to work early, or choose formula.

A more balanced message would support breastfeeding while clearly stating that safe formula feeding is medically appropriate when breastfeeding is not possible or not chosen.

Subscribe now

Infant and toddler nutrition

This section is generally appropriate. It recommends exclusive breastfeeding for about 6 months, iron-fortified infant formula when breast milk is not available, introduction of solid foods at about 6 months, and continued breastfeeding as mutually desired. It also acknowledges formula safety and FDA testing.

The one concern is tone. It should avoid implying that formula is second-best in a moral sense. Clinically, the key issue is safe, adequate infant nutrition.

Mental health resources for mothers

This section is strong. It states that postpartum depression affects about 1 in 8 women and gives the maternal mental health hotline, 1-833-TLC-MAMA, plus 988 for suicidal crisis. That is appropriate, concrete, and potentially lifesaving.

The section would be stronger if it also mentioned anxiety, OCD, PTSD after traumatic birth, postpartum psychosis, intimate partner violence, and the need for urgent care when there are thoughts of self-harm, harm to the baby, mania, psychosis, or inability to sleep.

Adoption resources

This section is highly selective. Moms.gov links to Lifeline Adoption, Focus on the Family, and BraveLove. These may provide adoption-related support, but the selection is not neutral. Adoption counseling should include independent legal advice, grief counseling, coercion safeguards, financial-conflict disclosure, birth-parent rights, revocation periods, and state-specific law.

A federal site should not present ideologically aligned adoption resources without also linking to neutral legal, social work, and state child-welfare resources.

Early Head Start

This section is appropriate and evidence-aligned in concept. It lists prenatal education, nutrition support, parenting education, maternal mental health screening, home visiting, and care coordination. These are legitimate supports for low-income pregnant women and families.

This is one of the best parts of the site because it routes users toward structured public programs rather than ideologically filtered counseling.

Additional resources

The additional resources section is mostly useful. It links to child welfare, safe sleep, CDC pages on tobacco, alcohol, cannabis, STIs, toxoplasmosis, HIV, diabetes, gestational diabetes, hypertension, depression, medication use, emergency preparedness, workplace reproductive health, environmental health, and radiation exposure. These are appropriate topics for a maternal-health portal.

The weakness is organization. The page mixes solid clinical public health resources with political branding and ideologically selected pregnancy-center pathways. That mixture reduces trust.

Moms.gov Conscience Overview PDF

This PDF is the most ideologically explicit part of the site. It frames pregnancy, childbirth, newborn care, vaccines, pediatric services, end-of-life care, and refusal of treatment through “conscience protections.” It explains that federal law protects both families and health care entities in certain settings when religious beliefs or moral convictions shape care decisions. It also emphasizes provider, plan, trainee, and institutional protections for declining to perform, assist with, pay for, cover, or refer for certain services, including abortion and sterilization.

This is not ordinary patient education. It is a rights-and-refusal document centered on religious and moral objection. Some of the legal information may be accurate, but the ethical balance is incomplete. A patient-facing maternal health site should also explain the patient’s right to medically indicated care, emergency stabilization, evidence-based counseling, referral pathways, and freedom from abandonment. It should not elevate institutional conscience without equal attention to patient access, safety, and informed consent.

Bottom line

Moms.gov is not simply a bad website. It contains useful links to FQHCs, breastfeeding support, maternal mental health services, Early Head Start, CDC pregnancy resources, and infant nutrition guidance. Those are legitimate public health resources.

But the site has a major ethical flaw: it places ideologically selected pregnancy-center referrals inside an official federal maternal-health resource without making the non-referral limitation clear enough. It also embeds political branding and conscience-protection framing into what should be a clinically neutral pregnancy resource.

The concise peer-review conclusion would be:

Moms.gov provides some valid maternal and child health resources, but it fails as a neutral government pregnancy-information portal because it mixes evidence-based public health links with politically branded programs, ideologically selected adoption and pregnancy-center referrals, and an explicit conscience-rights framework. Pregnant women deserve public resources that clearly distinguish medical care from peer support, evidence-based counseling from ideological counseling, and comprehensive reproductive health services from non-referring pregnancy centers.

That is why https://optionline.org/ deserves careful review.

OptionLine presents itself as a pregnancy help service for women facing an unintended pregnancy. It offers phone, text, chat, and referral to local pregnancy centers. On the surface, this appears helpful. The problem is not that support exists. The problem is that the support is not clinically neutral, while the language often sounds like neutral pregnancy-options counseling.

It’s Ideological:

Ideological, in this context, means that the information is shaped by a prior moral, religious, or political position rather than by balanced clinical evidence and patient-centered informed consent. The problem is not that an organization has values. The problem is when those values determine which medical options are emphasized, minimized, delayed, or excluded while the service presents itself as neutral counseling.

Subscribe now

The most important disclosure on the site is that OptionLine and its participating pregnancy centers provide peer counseling and information about pregnancy options, but “do not offer or refer for abortion services.”

That matters.

A woman who is considering abortion may believe she is entering a neutral counseling pathway. In reality, she is being routed into a network that has already excluded one legal medical option from referral.

From a peer-review perspective, this is a major limitation in counseling validity.

The site provides some accurate basic information. It correctly notes that missed periods can occur for reasons other than pregnancy. It correctly encourages pregnancy testing. It correctly states that ultrasound can assess viability and help identify ectopic pregnancy. These are reasonable points.

But the site repeatedly overstates the role of ultrasound by suggesting that only ultrasound can confirm pregnancy. That is not clinically accurate. A positive urine or serum hCG test confirms biochemical pregnancy. Ultrasound confirms location, gestational age, and viability when clinically indicated. This distinction matters because overstating the need for ultrasound can delay care, especially abortion care, where time affects access, cost, legal options, and procedural choices.

The abortion-related pages are the most concerning. They frame abortion as a “big decision” requiring confirmation, reflection, and awareness of risk. None of that is inherently wrong. Every medical decision deserves informed consent. But informed consent requires balanced information. The site emphasizes abortion risk, possible emotional harm, and the need for safety checks, while giving far less attention to the medical risks of continuing pregnancy, childbirth, delayed abortion access, or coercive counseling.

This is not balanced risk communication. It is selective risk framing.

The medication abortion page identifies mifepristone and misoprostol, but uses language such as “chemical abortion” and describes progesterone reduction in emotionally charged terms. It also implies that ultrasound is generally needed before medication abortion. That is not consistent with contemporary evidence-based care. ACOG states that medication abortion through 70 days of gestation is safe and effective, and that ultrasound is not always required when gestational age and ectopic pregnancy risk can be assessed clinically.¹

The surgical abortion page is also problematic. It describes aspiration and dilation procedures, but uses language that emphasizes fetal removal and retained “fetal body parts.” That is not standard patient-centered clinical language for early aspiration abortion. It may be technically related to later procedural concerns, but the emphasis is disproportionate and emotionally weighted.

Share

The emergency contraception page raises another major evidence issue. It claims emergency contraception may prevent implantation or act as an abortifacient. The best available evidence does not support that claim for levonorgestrel emergency contraception. Current evidence indicates that levonorgestrel emergency contraception works mainly by delaying or inhibiting ovulation and does not show a meaningful post-ovulatory anti-implantation effect.² ³

The adoption and parenting pages are more supportive in tone, but they are still incomplete. Adoption is presented largely as a structured option, with open, semi-open, and closed models. Yet the page gives insufficient attention to grief, legal finality, possible coercion, agency incentives, and the need for independent counseling. Parenting is presented with offers of support, but without enough discussion of medical risk, housing insecurity, intimate partner violence, financial hardship, postpartum depression, or access to obstetric care.

The “after abortion support” material is somewhat more balanced, because it acknowledges that women may feel relief, sadness, regret, or mixed emotions. That is closer to real clinical experience. However, the broader implication that abortion commonly causes delayed psychological harm is not supported by high-quality evidence. Mental health outcomes after abortion are strongly shaped by prior mental health, stigma, coercion, intimate partner violence, social support, and life circumstances. Abortion itself should not be presented as a general cause of long-term mental health harm.⁴

The ethical problem is transparency.

Subscribe now

Pregnant women deserve help. They deserve kindness. They deserve time to think. They deserve support with parenting, adoption, abortion, prenatal care, housing, safety, insurance, and mental health. But they also deserve to know whether the person or organization counseling them is neutral, medical, religious, ideological, peer-based, anti-abortion, or non-referring.

A public pregnancy resource pathway should not blur those categories.

If a government website lists or amplifies pregnancy resources, it should apply basic quality standards.

First, pregnancy information should be medically accurate.

Second, abortion, contraception, and emergency contraception content should reflect mainstream evidence.

Third, counseling services should clearly disclose what they do and do not provide before a woman shares personal information.

Fourth, non-referral for abortion should be stated prominently, not buried in a disclaimer.

Fifth, public agencies should distinguish peer support from medical care.

This is not about whether pregnancy centers should exist. They can provide material help, emotional support, parenting resources, and community assistance. The issue is whether they should be presented within government-linked pregnancy resources without a clear, evidence-based warning that they do not provide or refer for abortion care.

In clinical medicine, we would not call a consultation neutral if one legal, evidence-based option had been removed before the patient entered the room.

Public health communication should meet the same standard.

Pregnant women do not need filtered information. They need accurate information. They do not need ideological navigation disguised as options counseling. They need transparent pathways to qualified care.

That is the standard government pregnancy resources should meet.

Page-by-page evidence review

Home page. The home page presents OptionLine as a place to obtain help with an unexpected pregnancy through phone, text, chat, and referral. That sounds supportive, but the limitation is central: the site connects women to a pregnancy-center network that does not provide or refer for abortion services. A public-facing pregnancy resource should make that limitation obvious before a woman enters a counseling pathway.

Pregnancy Overview. This page gives some reasonable basic information. It notes that a missed period does not always mean pregnancy and that testing is needed. The problem is its repeated suggestion that ultrasound is necessary to “confirm” pregnancy. Clinically, a positive urine or serum hCG test confirms biochemical pregnancy. Ultrasound confirms location, gestational age, and viability when indicated.

Early Signs and Symptoms of Pregnancy. This page is mostly accurate in stating that early pregnancy symptoms are nonspecific. Breast tenderness, nausea, fatigue, urinary frequency, and missed menses can occur in pregnancy but can also occur for other reasons. The page appropriately points women toward pregnancy testing. Its weakness is that it funnels users into the same non-neutral service pathway.

Pregnancy Tests. The pregnancy-test page correctly explains that home urine pregnancy tests are most reliable after a missed period and may be falsely negative if taken too early. However, it again overstates ultrasound as the only way to confirm pregnancy. That is not medically precise. The more accurate statement is that ultrasound may be needed to confirm intrauterine location and viability.

“I Don’t Know What to Do.” This page frames abortion, adoption, and parenting as options, which is appropriate in principle. The problem is tone. Abortion is described as “the most immediately permanent” option, which is morally weighted language. Continuing pregnancy, giving birth, parenting, and adoption also have permanent consequences. Balanced counseling should describe all options with the same ethical and emotional neutrality.

Considering Abortion. This page advises women to confirm pregnancy and consider gestational age and viability before abortion. Those points are not wrong. The ethical problem is that the page discusses abortion while routing women to centers that do not provide or refer for abortion. That creates a mismatch between what the user may think she is receiving and what the service actually offers.

Medication Abortion. The medication abortion page identifies mifepristone and misoprostol, but the language is not clinically neutral. It uses terms such as “chemical abortion” and frames progesterone reduction in a way that can sound alarming rather than explanatory. It also implies that ultrasound is generally needed before medication abortion, although evidence-based protocols do not always require ultrasound when dating and ectopic risk can be assessed clinically.¹

Surgical Abortion. This page describes aspiration and dilation procedures, but the wording emphasizes fetal removal and retained “fetal body parts.” That language is not typical patient-centered medical counseling for early aspiration abortion. The page does not give a balanced comparison of procedural safety, gestational age, complication rates, or the risks of delaying care.

Abortion Cost. This page correctly states that abortion cost varies by gestational age, location, procedure type, anesthesia, and other factors. But it is incomplete. It does not sufficiently explain that delay itself can increase cost and reduce available options. Referral to non-abortion-providing centers may therefore have practical consequences for women seeking timely care.

Abortion Safety Checklist. The checklist encourages women to ask about clinician qualifications, emergency planning, and follow-up. Those are reasonable questions. The weakness is asymmetry.

The page raises concerns about abortion safety but does not equally address the risks of continuing pregnancy, the risks of childbirth, or the clinical consequences of delayed abortion access.

After Abortion Support. This page is more balanced than some others because it recognizes that women may feel relief, sadness, regret, or mixed emotions after abortion. That reflects real clinical variation. However, any implication that abortion commonly causes delayed long-term psychological harm should be treated carefully. The evidence does not support abortion as a general independent cause of long-term mental health harm.⁴

Considering Adoption. The adoption page explains open, semi-open, and closed adoption in accessible language. That is useful. But it is incomplete as counseling. Adoption involves grief, legal finality, power imbalance, agency incentives, and potential coercion. A woman considering adoption should have access to independent counseling, not only support from organizations with a preferred pregnancy-continuation framework.

Considering Parenting. The parenting page offers support and encourages women to think about family, finances, and practical needs. That is appropriate. But the discussion is too limited. Parenting decisions must also address medical risk, housing, insurance, intimate partner violence, mental health, childcare, employment, and access to obstetric care. Supportive language is not enough.

“Am I Ready to Have a Baby?” This page offers reflective questions about readiness for parenting. That can be helpful for some women. The concern is not the questions themselves. The concern is where the questions lead. If the pathway leads to a network that does not refer for abortion, that limitation should be stated clearly before the user engages.

Morning-After Pill / Emergency Contraception. This is one of the weakest pages scientifically. The site suggests that emergency contraception may prevent implantation or act as an abortifacient. For levonorgestrel emergency contraception, the best evidence supports a primary mechanism of delaying or inhibiting ovulation, without good evidence of a clinically meaningful post-ovulatory anti-implantation effect.² ³

STDs and STIs. The STI pages appear to offer general sexual-health information. The evidence standard here should be straightforward: recommend testing, condom use, partner notification and treatment when appropriate, and referral for medical care. STI education should not be used mainly as an entry point into pregnancy-center counseling. It should direct users clearly to qualified testing and treatment.

Get Help / Find a Center. The help and referral pages are the practical endpoint of the site. They route women to local centers, phone support, text support, and chat. This is where transparency is most important. Before any personal information is shared, the user should be told plainly that the referred centers provide peer counseling and support but do not provide or refer for abortion services.

Bottom line. Taken page by page, the site contains some accurate basic pregnancy information, but its abortion and emergency contraception content is selectively framed and not consistently evidence-based. Its central ethical problem is not simply that it opposes abortion referral. Organizations may hold that position. The problem is that a pregnancy-options website, especially one appearing in a public resource ecosystem, should disclose that position prominently and should not present non-neutral counseling as neutral medical guidance.

References

1. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins. Medication abortion up to 70 days of gestation: ACOG Practice Bulletin No. 225. Obstet Gynecol. 2020;136(4):e31-e47. doi:10.1097/AOG.0000000000004082. PMID:32804884.

2. Endler M, Li R, Gemzell Danielsson K. Effect of levonorgestrel emergency contraception on implantation and fertility: a review. Contraception. 2022;109:8-18. doi:10.1016/j.contraception.2022.01.006. PMID:35081389.

3. Gemzell-Danielsson K, Berger C, Lalitkumar PGL. Emergency contraception: mechanisms of action. Contraception. 2013;87(3):300-308. doi:10.1016/j.contraception.2012.08.021. PMID:23114735.

4. Horvath S, Schreiber CA. Unintended pregnancy, induced abortion, and mental health. Curr Psychiatry Rep. 2017;19(11):77. doi:10.1007/s11920-017-0832-4. PMID:28905259.

Summary

A 33-week pregnant woman posted to r/pregnant after an unplanned hospital visit. She had spotting and silent contractions. The doctors gave her water and a snack. Everything stopped. She was sent home fine. Her post -- written in all caps -- went viral within hours: 493 upvotes, 111 comments. The message was simple: she thought she was hydrated because she was urinating frequently. She was wrong. Frequent urination in pregnancy is caused by fetal pressure on the bladder, not by adequate fluid intake. The two are not the same. Her uterus was cramping from dehydration. The thread quickly filled with identical stories: women at 21, 28, and 35 weeks who had gone to labor and delivery for the same reason and were sent home with water.

Evidence-Based Commentary

Dehydration-triggered uterine contractions are not folklore. The mechanism is physiologically real. Myometrial smooth muscle, like all muscle, is sensitive to electrolyte balance and intravascular volume. Dehydration raises plasma osmolality, triggers antidiuretic hormone (ADH) release, and -- crucially -- stimulates oxytocin co-secretion from the posterior pituitary. Oxytocin drives uterine contractions. This is not a controversial pathway. It is well documented.

The misconception at the center of this post -- that frequent urination equals adequate hydration -- is one of the most common errors I hear from pregnant patients. It needs to be corrected at every prenatal visit. In pregnancy, urinary frequency is driven primarily by the growing uterus compressing the bladder, reducing its functional capacity. A woman can void every 45 minutes and still be volume-depleted if her fluid intake is insufficient. Urine color is a better -- though imperfect -- clinical proxy: pale yellow suggests adequate hydration; dark yellow or amber signals the opposite. One commenter in the thread noticed her urine looked like apple juice at the time of delivery despite hourly voiding. That is not an edge case. That is a predictable consequence of confusing frequency with volume.

How much fluid does a pregnant woman actually need? The honest answer is: it depends, and the guidance in this thread ranged from 100 to 150 ounces per day. ACOG does not issue a specific numeric daily fluid target for uncomplicated pregnancy. The Institute of Medicine (now the National Academy of Medicine) recommends approximately 2.3 liters (roughly 78 ounces) of total water per day from all sources, with higher needs in hot climates, with physical activity, or in the setting of vomiting. A midwife recommending 150 ounces daily is operating well outside evidence-based guidelines -- and for a patient with cardiac or renal compromise, that level of intake could be genuinely dangerous. Blanket high-number targets are not evidence-based. Context matters.

One commenter stated plainly that plain water causes dehydration and that electrolytes must always accompany fluid intake. This is wrong. Electrolyte supplementation is beneficial in specific clinical settings: hyperemesis gravidarum, excessive sweating, or prolonged exertion in heat. For a healthy pregnant woman sitting at home, plain water is appropriate hydration. Overuse of electrolyte packets -- particularly high-sodium formulations -- can contribute to edema and, in susceptible patients, worsen hypertensive disorders. The endorsement of commercial electrolyte products as routine pregnancy supplements, driven partly by influencer marketing, is not supported by evidence.

The thread also surfaced a real clinical challenge: first-trimester nausea that makes adequate fluid intake genuinely difficult. The community’s responses here were largely practical and reasonable -- popsicles, diluted juice, small frequent sips, Pedialyte. From a clinical standpoint, the key threshold is this: if a patient cannot keep any fluids down for more than 24 hours, or if she shows signs of ketonuria, orthostatic hypotension, or weight loss, she needs IV hydration and evaluation for hyperemesis gravidarum -- not Reddit advice. The community is rightly encouraging each other to drink; the limits of that encouragement are what providers need to establish clearly.

What It Means

This thread represents a real and preventable gap in prenatal education. Women are reaching 33 weeks of pregnancy -- past viability, well into the third trimester -- without understanding that frequent urination does not mean adequate hydration. That is a failure of prenatal counseling, not a failure of the patient. The information she needed was simple, practical, and potentially saved her from a much more complicated outcome. If this woman had been farther from a hospital, if she had dismissed the spotting, if the contractions had continued -- the stakes escalate quickly.

Obstetric providers should address hydration directly at every visit in the third trimester: not a pamphlet, not a general reminder, but a specific conversation about urine color as a monitoring tool, the inadequacy of urinary frequency as a hydration proxy, and individualized fluid targets based on the patient’s size, activity level, climate, and clinical picture.

Subscribe now

My Take

I have watched this happen on labor and delivery more times than I can count. A patient arrives with contractions she cannot feel, a fetal heart rate that looks fine, and a urine sample that tells the whole story. We give her two liters of IV saline. The contractions stop. She goes home. The visit should never have happened.

What strikes me about this thread is not the original post -- that story is familiar. What strikes me is the noise. Women are getting conflicting fluid targets from their providers: 100 ounces from one OB, 150 from a midwife, 120 from the internet. Nobody is explaining why. Nobody is giving them a tool they can use at home -- like urine color -- to actually monitor themselves. Instead, they are collecting numbers and doing the math wrong.

And underneath all of it: a perfectly correctable misconception. Frequent urination does not mean you are hydrated. In pregnancy, it means you have a baby sitting on your bladder. Every prenatal provider should say that sentence out loud, at every third-trimester visit, until it sticks. It takes ten seconds. It might prevent a hospital admission.

The Visit That Hadn’t Changed in 20 Years

Karen was 46 and prided herself on staying on top of her health. Annual mammogram, check. Pap smear, check. Cholesterol, check. She walked three miles a day, ate salads for lunch, took a multivitamin, and hadn’t missed a doctor’s appointment in a decade.

So when she woke up one morning and couldn’t remember the word for “refrigerator,” she figured she was just tired. When her periods started coming every two weeks — then not at all for three months — she assumed stress. When she lay awake until 2 a.m. with her heart pounding for no reason, she Googled “anxiety in your forties” and ordered magnesium gummies.

What Karen didn’t know — because nobody told her — was that she was in perimenopause. That her bone density had been quietly declining for five years without a single scan. That the “heart pounding” deserved a cardiovascular workup, not a supplement. That her mother’s colon cancer diagnosis three years ago should have triggered a colonoscopy referral that never happened. That the antidepressant her primary care doctor prescribed for her insomnia was actually masking symptoms that had a hormonal explanation.

Karen’s doctors were all competent. Her visits were all thorough — by the standards of a 25-year-old patient. But Karen wasn’t 25 anymore, and her medical care hadn’t caught up.

The Decade Nobody Prepares You For

Your forties are when the math changes.

Cancer risk rises. Cardiovascular disease — the number one killer of women, and it’s not even close — starts its slow climb. Bone loss accelerates, especially in the years surrounding menopause. Metabolic shifts make weight management genuinely harder (no, it’s not your imagination). Thyroid function can quietly go sideways. Autoimmune conditions that were simmering for years can surface. And the hormonal transition of perimenopause can start as early as your late thirties, bringing symptoms that mimic — and get misdiagnosed as — depression, anxiety, ADHD, thyroid disease, cardiac arrhythmia, and a dozen other conditions.

This is the decade where early detection matters most and where missed opportunities are hardest to recover from.

And yet, for millions of women, the annual visit at 44 looks almost exactly like the annual visit at 28. Same checklist. Same questions. Same fifteen minutes. Same “everything looks fine, see you next year.”

It shouldn’t.

This Post Is Your Wake-Up Call — And Your Cheat Sheet

I’ve practiced obstetrics and gynecology for over 50 years. I’ve watched women in their forties get spectacular care and I’ve watched women in their forties fall through every crack in the system. The difference almost always comes down to the same thing: whether someone asked the right questions at the right time.

This post is for every woman over 40 who suspects her medical care is still running on the script it was written when she was in her twenties. It’s for the woman who feels like something has shifted but can’t get anyone to take it seriously. It’s for the woman who wants to be proactive but doesn’t know what to ask.

These are the ten questions that should be part of every medical conversation after 40. If your doctor isn’t asking them, bring them yourself.

Subscribe to Obstetric Intelligence for more straight talk about women’s health — and share this with every woman in your life who’s hit the decade where everything changes and nobody handed her the manual.

Read more

Norovirus does not check your booking history. A placental abruption at sea is the same emergency for a first-time cruiser as for a repeat cruiser. There is no biological mechanism by which prior cruise experience protects a pregnancy. The “first cruise” caveat is hedge language. It is there to soften a recommendation, not to make a medical distinction.

Strip it out and the sentence reads correctly: planning a cruise while you are pregnant is not a good idea. ACOG hedges. The CDC Yellow Book softens. The cruise lines themselves write the warning into their booking terms rather than their marketing. All point in the same direction.

The Cruise Environment Itself

Cruise ships concentrate large populations into shared dining, shared ventilation, shared sanitation, and continuous passenger turnover at ports. The CDC’s Vessel Sanitation Program defines an outbreak as 3 percent or more of passengers or crew on a single voyage reporting gastrointestinal symptoms. By that threshold, the CDC confirmed 16 outbreaks on cruise ships in calendar year 2024, the largest annual count since 2012. (2) Norovirus was the most common pathogen identified.

Norovirus does not cross the placenta. The dehydration it causes is the obstetric problem. Severe dehydration can precipitate uterine contractions, reduced fetal movement, and electrolyte disturbances that are far harder to manage in a ship’s medical center than in a hospital. Influenza and COVID-19 produce the same pattern in respiratory form.

Geography Becomes Treatment

The CDC Yellow Book 2026, published April 2025, is unusually direct on this point. Travel health risks during cruises include “the possibility of delayed care while at sea.” (3,4) In ordinary medicine, that phrase sounds abstract. In obstetrics, it is the entire issue. Pregnancy emergencies do not announce themselves. Preterm labor, placental abruption, severe preeclampsia, hemorrhage, ectopic rupture, and pulmonary embolism develop in hours in women who were completely well that morning.

The peer-reviewed literature now includes a published case report of a young woman whose ruptured ectopic pregnancy was identified by handheld ultrasound at sea, requiring emergent helicopter evacuation to a shoreside operating room. (5) That is the best case scenario for an obstetric emergency on a ship. It depends on weather, on aircraft availability, and on the ship’s medical team correctly identifying the diagnosis. The worst case scenario is a delivery at sea at a gestational age the ship cannot support. The Royal College of Obstetricians and Gynaecologists reaches the same conclusion in calmer prose: the central concern with pregnancy travel is preterm labour or an obstetric emergency developing during the journey. (6)

Subscribe now

The 24-Week Cutoff Is Not a Reassurance

Most cruise lines stop boarding at 24 weeks. This is widely misread as a safety reassurance. It is the opposite. The 24-week threshold reflects the lower bound of neonatal viability with intensive care. The cruise lines stop boarding at 24 weeks because beyond that point a preterm delivery onboard would require a neonatal intensive care unit they cannot provide. The policy is a liability decision, not a medical safety standard.

The medical risks before 24 weeks remain. Miscarriage, ectopic rupture, severe hyperemesis with electrolyte disturbance, venous thromboembolism, and previable preterm labor all occur in the first and second trimesters. ACOG, the CDC, and the RCOG agree that pregnancy emergencies cluster in the first and third trimesters. (1,7,6) The second trimester is statistically the safest, but “safest” is not “safe at sea.”

What This Means for Pregnant Women

The decision to cruise during pregnancy is not really about whether you will have a complication. The probability for any single woman on any single cruise is low. The decision is what happens if you are the woman who does. At home, an unexpected emergency means an ambulance, a hospital, an operating room, and a neonatal team within minutes. On a cruise, the same emergency means a ship infirmary designed for stabilization, a captain making routing decisions, a possible helicopter evacuation, and a foreign hospital that may be hours or a day away. (5,8) The medical center on a ship is not a hospital. It is a stabilization unit with limited diagnostic and surgical capability, not equipped to safely deliver a preterm infant, manage a postpartum hemorrhage, or perform an emergency cesarean.

Insurance is a separate problem most pregnant women do not anticipate. Standard United States health insurance often does not cover medical care delivered onboard a cruise ship or at a foreign hospital. Travel insurance with medical evacuation coverage is essential, but most policies have pregnancy clauses worth reading carefully. A travel insurance policy that excludes complications of pregnancy is not adequate coverage for a pregnant cruiser.

My Take

Patient autonomy is the foundation of obstetric ethics, and autonomy depends on honest counseling. A clinician who avoids telling a pregnant patient the truth about cruise travel because the conversation is uncomfortable is not respecting autonomy. The clinician is undermining it. The professional responsibility model requires recommending the best evidence-based option, not handing a patient a menu and stepping back.

ACOG hedges with “may not be a good idea” and adds an incoherent qualifier about first-time cruisers. The CDC writes about “the possibility of delayed care.” The cruise lines write about gestational viability cutoffs. All are saying the same thing without saying it. I am not in the liability business. A cruise during pregnancy is a low-probability, high-consequence decision. Most cruises will be uneventful. The ones that are not are the reason this advice exists.

Bottom Line

Pregnancy is stable until the moment it is not. When an obstetric complication occurs, minutes and access determine outcome. A cruise ship cannot provide either.

Skip the cruise. Choose a vacation within reach of advanced obstetric and neonatal care. The scenery is not the point. The proximity is.

If this analysis was useful, subscribe to ObGyn Intelligence. Evidence-based, direct, and unhedged.

References

1. American College of Obstetricians and Gynecologists. Travel during pregnancy. ACOG Patient FAQ. Available at: https://www.acog.org/womens-health/faqs/travel-during-pregnancy

2. Centers for Disease Control and Prevention. Outbreaks on cruise ships in VSP’s jurisdiction. Vessel Sanitation Program. Available at: https://www.cdc.gov/vessel-sanitation/cruise-ship-outbreaks/index.html

3. Centers for Disease Control and Prevention. Cruise ship travel. In: Halsey ES, Angelo KM, Barnett ED, et al., editors. CDC Yellow Book 2026: Health Information for International Travel. Atlanta (GA): Centers for Disease Control and Prevention; 2025. Available at: https://www.cdc.gov/yellow-book/hcp/travel-air-sea/cruise-ship-travel.html

4. Galang RR, Roy SC. Pregnant travelers. In: Halsey ES, Angelo KM, Barnett ED, et al., editors. CDC Yellow Book 2026: Health Information for International Travel. Atlanta (GA): Centers for Disease Control and Prevention; 2025. Available at: https://www.cdc.gov/yellow-book/hcp/family-travel/pregnant-travelers.html

5. Boniface KS, Aalam AA, Liu YT, Galagan J, Buisson E, Shokoohi H. A cruise ship emergency medical evacuation triggered by handheld ultrasound findings and directed by tele-ultrasound. Int Marit Health. 2020;71(1):20-23. PMID: 32212147.

6. Royal College of Obstetricians and Gynaecologists. Air travel and pregnancy. Scientific Impact Paper No. 1. London: RCOG; 2013. Available at: https://www.rcog.org.uk/media/jw4jyghl/sip_1.pdf

7. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Air travel during pregnancy. ACOG Committee Opinion No. 746. Obstet Gynecol. 2018;132(2):e64-e66. PMID: 30045212.

8. Hezelgrave NL, Whitty CJM, Shennan AH, Chappell LC. Advising on travel during pregnancy. BMJ. 2011;342:d2506. doi: 10.1136/bmj.d2506.

Share

There is a chart that the health equity literature almost never shows. It is not complicated. It has four rungs. At the top sits commercial insurance, the Blue Cross PPO, the employer-sponsored United Healthcare plan, the Aetna gold card.

At the bottom sits Medicaid.

In between, occupying the middle two rungs that are almost never discussed, sit the ACA Marketplace plans and the union-negotiated Taft-Hartley health funds.

The conversation about maternal health disparities focuses almost exclusively on the distance between the top and bottom rungs. It treats the problem as binary: Medicaid patients cannot access quality care, and everyone else can.

This framing is wrong, and the error is not minor.

It mischaracterizes who is excluded, obscures the mechanism of exclusion, and leads to policy interventions that address only the most extreme cases while leaving a much larger population without adequate access.

Understanding the full ladder is essential to understanding why Black maternal mortality cannot be solved by addressing Medicaid alone.

What Physicians Actually Get Paid

American physicians are paid differently depending on who is paying the bill. This is not controversial; it is the architecture of the system.

What is underappreciated is how extreme the differences are, and how directly those differences translate into access decisions at the practice level.

Medicaid pays physicians approximately 72 percent of what Medicare pays for the same obstetric services. This ratio has been essentially unchanged since 2008, meaning that Medicaid rates have not kept pace with inflation, practice costs, or the rising administrative burden of participation. When a practice calculates the cost of accepting a Medicaid patient, including the billing complexity, the prior authorization demands, and the 17.4 percent claim loss rate from billing problems, the effective reimbursement is substantially below even the nominal 72 percent figure.

Medicare rates themselves are not generous. Commercial insurance, the benchmark against which faculty practices build their revenue models, pays physicians on average two to three times what Medicare pays. One analysis found that commercial payers paid physicians approximately 270 percent of the Medicare rate for many services. This means the effective reimbursement gap between a Medicaid patient and a commercial insurance patient, for identical obstetric services delivered by the same physician in the same office, can approach a factor of four.

A faculty obstetrician who sees 20 patients per day, replacing commercial patients with Medicaid patients, is not making a philosophical statement about equity. She is making a financial decision that has direct consequences for her practice’s ability to employ staff, maintain equipment, and remain viable. The ethics of that decision are legitimate to debate. Its economics are not.

The Middle Rungs: ACA Marketplace Plans

The Affordable Care Act created a marketplace for individual health insurance that now covers more than 21 million Americans. For many low- and moderate-income individuals who do not qualify for Medicaid but cannot access employer-sponsored coverage, the marketplace is their only option. This population includes a significant proportion of minority women of reproductive age.

What is rarely communicated to these women, and almost never discussed in the maternal health equity literature, is that marketplace plans reimburse physicians at rates substantially below what employer-sponsored commercial plans pay. A 2024 Health Affairs analysis using comprehensive claims data found that in 2021, marketplace prices were 152 percent of Medicare rates, while employer small-group plans paid 179 percent of Medicare rates. For professional services specifically, marketplace plans paid 6.9 percent less than employer small-group plans. For outpatient hospital services, the gap was 26.3 percent.

This means that a woman who purchases marketplace coverage, believing she has real insurance, is holding a card that many physicians and practices price below their threshold for participation. She is not on Medicaid. She is not uninsured. She is in a middle category that receives almost no policy attention, yet represents a genuine and growing barrier to accessing the most sought-after obstetric providers in high-cost urban markets.

In Manhattan, where faculty practice overhead is among the highest in the country and competition for commercial patients is intense, a marketplace plan functions economically more like Medicaid than like a Blue Cross PPO. The physician’s list on her website reads: Aetna, Cigna, United, Blue Cross, Medicare. The marketplace plan her patient purchased may carry one of those brand names, but the reimbursement contract behind it is a different instrument entirely. The plan name on the card is not the same as acceptance by the provider.

The Third Rung: Union and Taft-Hartley Plans

Labor unions have historically been among the strongest advocates for comprehensive health coverage. This is genuine and important. But union health plans, structured as Taft-Hartley multiemployer trusts, are designed to contain costs through negotiated reimbursement agreements that typically pay below standard commercial rates.

A hospital worker covered by a union health plan, a construction laborer, a hotel employee, a transit worker: these are not uninsured people. They are working people with genuine coverage. But their coverage negotiates physician reimbursement at rates that fall below what the same physician earns from standard commercial insurance patients. In markets where physician practices have more commercial patients than they can accommodate, union plan patients join marketplace patients in a secondary tier of access that is rarely named and almost never measured.

This matters for the maternal mortality conversation because union members are disproportionately minority workers in urban settings. In New York City, a significant proportion of the workforce covered by Taft-Hartley plans is Black and Hispanic. These workers have health insurance. They do not have the same insurance, from the physician’s perspective, as the white-collar employee with an employer-sponsored PPO in the same city.

The Practical Geography of Exclusion

When you map these reimbursement tiers onto the faculty practice landscape of a city like Manhattan, the picture that emerges is not a simple Medicaid exclusion. It is a gradient. The faculty obstetrician who accepts Aetna Preferred and United Choice Plus and declines Medicaid, marketplace plans, and union funds is not drawing a line at poverty. She is drawing a line at reimbursement adequacy. And the population below that line is far larger, and far more racially concentrated, than the Medicaid population alone.

This gradient creates a category of patients who are effectively invisible in the access literature: women who are insured, who do not qualify for safety-net programs, who are not counted among the uninsured, but who cannot access the care they nominally have coverage for because the reimbursement behind their coverage does not meet the threshold of participation for the practices they would most benefit from seeing.

A pregnant woman on a silver marketplace plan whose ob-gyn appointment is at a resident clinic is not a Medicaid failure. She is an insurance market failure. Her story does not appear in the Medicaid access statistics. She appears nowhere in the policy conversation. She is, however, delivering at a different hospital than her neighbor with the employer-sponsored Blue Cross plan, and that difference in delivery location is associated, in the published literature, with nearly half the racial disparity in maternal morbidity.

Why This Framing Matters for Policy

The binary Medicaid framing of the access problem leads to binary solutions: raise Medicaid rates, expand Medicaid eligibility, increase Medicaid enrollment. These are all necessary and worth pursuing. But they address only the bottom rung of a four-rung ladder while patients in the middle two rungs continue to be routed away from the highest-quality obstetric care in the country.

A comprehensive structural response to Black maternal mortality requires acknowledging that the reimbursement hierarchy affects access across the full insurance spectrum, not just at the Medicaid threshold. It requires transparency from faculty practices about which insurance plans they actually accept, not just which insurance brands they nominally participate in. And it requires an honest conversation about the obligation of academic medical centers, whose research funding, tax exemptions, and national rankings depend in part on their public mission, to provide equitable access across the insurance spectrum they serve.

The ladder is real. It has four rungs. Pretending it has two does not change how many patients fall off it.

My Take

I have reviewed the insurance plans accepted by faculty obstetric practices at New York’s major academic medical centers. The lists on their websites are long and impressively comprehensive-looking. Aetna. Cigna. United. Oxford. Empire. They do not mention which tier of those plans they accept. They do not mention that a marketplace Aetna plan is not the same financial instrument as an employer Aetna PPO. They do not explain that a woman comparing insurance options during open enrollment has no way of knowing whether the faculty practice she aspires to reach will treat her plan as equivalent to a gold-standard commercial plan or as a near-Medicaid patient.

This lack of transparency is not an accident. It is professionally convenient. It allows practices to appear broadly accessible while operating with a patient panel that skews heavily toward the most generously reimbursed plans. It allows institutions to publish on health equity while their faculty practices optimize for the most profitable patients.

The fix here is not complicated. Every faculty practice that accepts public funding, that trains residents, that operates under a medical school or hospital system with tax-exempt status, should be required to disclose not just which insurance brands it participates in, but which tier of each plan it accepts and at what reimbursement level. The public has a right to know. The patients trying to navigate this system deserve transparency. And the academic medical enterprise that claims to be committed to health equity should be able to withstand having its insurance acceptance practices made visible.

The ladder exists. Let us at least agree to look at all its rungs.

The series continues next week with Post 3: Two Doors, One Building — the documented two-tier system inside academic medical centers, the billing loophole that lets OB/GYNs enroll in Medicaid to capture deliveries while providing no prenatal care, and the Manhattan faculty practice observation with evidence. Post 3 is free. Posts 4 through 10 are for paid subscribers at obmd.com. Annual subscription: $60.

References

1. Zuckerman S, Goin D. How Much Will Medicaid Physician Fees for Primary Care Rise in 2013? Evidence from a Survey of Medicaid Physician Fees. Kaiser Commission on Medicaid and the Uninsured; 2012.

2. Dunn A, Gottlieb JD, Shapiro A, Sonnenstuhl DJ, Tebaldi P. A Denial a Day Keeps the Doctor Away. NBER Working Paper 29010. National Bureau of Economic Research; 2021.

3. McDermott D, Cox C, Rudowitz R, Garfield R. How Differences in Medicaid, Medicare, and Commercial Health Insurance Payment Rates Impact Access, Health Equity, and Cost. Commonwealth Fund; 2022.

4. Polsky D, Cidav Z, Swanson A. Marketplace Plans With Lower Premiums Have Comparable Access to Nearby Providers. Health Aff (Millwood). 2016;35(10):1842-1848.

5. Fiedler M, Bai G, Anderson GF. Providers Paid Substantially Less By Marketplace Nongroup Insurers Than By Employer Small-Group Plans, 2021. Health Aff (Millwood). 2024. doi:10.1377/hlthaff.2024.00913.

6. Berenson RA, Holahan J. Commercial Health Insurance Markups for Physician Services Over Medicare Prices Vary Widely by Specialty. Urban Institute; 2021.

7. Commonwealth Fund. How Unions Act as a Force for Change in Health Care Delivery and Payment. March 2019.

8. MACPAC. Physician Acceptance of New Medicaid Patients: Findings from the National Electronic Health Records Survey. Washington, DC: MACPAC; 2021.

A patient tells me she’s been trying to get pregnant “for a while” and it’s not working.

“How long have you been trying?” I ask.

“I don’t know, maybe six months? Maybe longer?”

“And when do you typically ovulate?”

Blank stare. “I’m not sure. We just... try a lot.”

I hear this constantly. Couples are told to “relax and let it happen,” so they don’t track anything. Then months pass, frustration builds, and when they finally seek help, they can’t answer basic questions about their cycles. We’re starting from scratch when we could have been months ahead.

Your Body Gives You a Fertility Window. Numbers Help You Find It.

Here’s the reality: you can only get pregnant during a narrow window each cycle. An egg lives 12 to 24 hours after ovulation. Sperm can survive up to five days in the reproductive tract. That gives you roughly six days per cycle when pregnancy is possible—the five days before ovulation and the day of ovulation itself.

Miss that window, and it doesn’t matter how often you have sex the rest of the month. Hit it, and your chances go up dramatically.

The problem is that ovulation doesn’t happen on the same day for everyone, and it doesn’t always happen on the same day for you. Tracking helps you find your window instead of guessing at it

The rest of this post is for paid subscribers.

Read more

I decided to find out.

I took two real clinical scenarios and asked them across three tiers of Claude:

Free, Pro, and Max.

What I found is not a sales pitch. It is a clinical observation. And like most clinical observations, the data matter more than the opinion.

Subscribe now

What are the tiers?

Claude is the AI made by Anthropic. It comes in several models, and the model you access depends on what you pay. The free tier uses Haiku, Anthropic’s fastest and lightest model. It is designed for quick answers and short tasks. Pro, at $20 per month, gives you Sonnet, a meaningfully more capable model, with five times more usage than the free plan. Max, at $100 or $200 per month, gives you Opus, Anthropic’s most powerful model, with priority access and the highest usage limits.

Think of it like hospital staffing. Free is the intern who has read the textbook. Pro is the senior resident who has also seen the cases. Max is the attending who has seen the cases, read the trials, and is about to tell you exactly why the textbook got it wrong.

For most tasks, free Claude is fine. For clinical reasoning under uncertainty, the tiers are not interchangeable. Here is the evidence.

Share

The scenarios

I chose two cases that most obstetric clinicians encounter: a preeclamptic patient at 29 weeks, and a patient with a prior spontaneous preterm birth at 27 weeks presenting at 18 weeks with a 15-millimeter cervix. Neither is a trick question. Both require real clinical judgment.

I asked each version of Claude: manage this patient, briefly. Then I read what came back.

What Free Claude said

Scenario 1: Severe preeclampsia at 29 weeks

Admit, monitor BP and labs. IV magnesium sulfate for seizure prophylaxis. Antihypertensives if BP is 160 over 110 or higher. Betamethasone for fetal lung maturity. Deliver if maternal or fetal status deteriorates.

Scenario 2: History of preterm birth at 27 weeks, now 18 weeks with cervical length 15 mm

High risk for recurrent preterm birth. Start vaginal progesterone. Consider cerclage given short cervix. Serial cervical length monitoring. Discuss signs of preterm labor. Refer to MFM.

Both answers are correct. Neither is wrong. If you posted either one on a medical board review forum, no one would mark it incorrect. But correct and complete are not the same thing. Free Claude gives you a checklist. It does not give you a clinical argument. It does not tell you why, when, or with what evidence. It does not tell you the 15-millimeter cervix plus prior 27-week birth is not just a risk factor but a dual indication that puts a cerclage placement window in front of you right now.

For a nurse triaging at intake, free Claude is useful. For clinical decision-making at the bedside, it is the floor, not the ceiling.

Subscribe to ObGyn Intelligence to read the Pro and Max responses, and to understand exactly what you are paying for — and whether it matters clinically.

Below, paid subscribers will find the Pro and Max responses to both scenarios, and my analysis of what distinguishes each tier clinically.

Read more

I decided to find out.

I took two real clinical scenarios and asked them across tiers of ChatGPT:

OpenAI’s public pricing page lists the current plan categories: Free, Go, Plus, Pro, Business, and Enterprise. Current U.S. list prices, in short:

• Free: $0/month.

• Go: about $8/month, availability and price vary by country.

• Plus: $20/month.

• Pro: $200/month.

• Business: $25/user/month billed annually, or $30/user/month billed monthly, minimum 2 users. OpenAI’s business pricing page lists the annual plan and notes the monthly billing price.

• Enterprise: custom pricing, contact sales.

Prompt: “What is the management of a preeclamptic patient at 29 weeks””

Free-tier style answer:
At 29 weeks, preeclampsia is managed with close maternal and fetal monitoring. The patient may need hospital admission, blood pressure control, lab testing, fetal surveillance, corticosteroids for fetal lung maturity, and magnesium sulfate if severe features are present. Delivery is considered if the mother or fetus becomes unstable.

Prompt: “How should I counsel a patient with prior preterm birth at 27 weeks now a cervix of 15 mm at 18 weeks?”

I would assume this means a singleton pregnancy, an asymptomatic patient, a prior spontaneous preterm birth at 27 weeks, and a transvaginal cervical length of 15 mm at 18 weeks. If the prior 27-week birth was medically indicated, PPROM, twins, fetal anomaly, or infection-related, counseling would change.

Free-tier style answer:
This patient is at high risk for another preterm birth. She should be referred to maternal-fetal medicine. Management may include cervical cerclage, vaginal progesterone, repeat cervical length monitoring, and counseling about warning signs such as contractions, bleeding, leaking fluid, or pelvic pressure. She should be followed closely.

Below is for paid subscribers only. Find the answers based on the tiers. The rest of this post is for paid subscribers.

Read more

A 2020 Cochrane review shows supervised pelvic floor training cuts that risk by 62%. Most women are told to wait and see. Most doctors have never heard about it. Here is what the evidence actually supports, and what to do about it.

A patient came to me frustrated. She had asked her prenatal team for pelvic floor physiotherapy during her third pregnancy. She was told she was being proactive. The implication was that proactive was unusual. She had also been advised to avoid sneezing where possible.

That exchange tells you everything you need to know about the state of antenatal pelvic floor care.

Subscribe now

The evidence does not support watchful waiting. It supports early, structured, supervised intervention. This post explains what the options are, what the data show, and exactly how to act on them.

How Common Is This?

Urinary incontinence during pregnancy is not a minor nuisance affecting a small subset of women. The weighted average prevalence across 36 observational studies with more than 2 million women is 41%. In the third trimester specifically, about 34 in 100 pregnant women report involuntary urine loss (1).

After delivery, the problem does not simply resolve.

At 6 weeks postpartum, prevalence is 24%.

By 12 months, it climbs back to 32% (2). Women who develop urinary incontinence during pregnancy carry a fivefold increase in odds of still having it at 7 years (OR 5.4, 95% CI 2.6 to 11.5) (3).

The pelvic floor also faces structural stress beyond the bladder. Pelvic organ prolapse, anal incontinence, and dyspareunia are all documented consequences of the mechanical and hormonal demands of pregnancy and delivery. These are not rare outcomes. Pelvic organ prolapse occurs in an estimated 14 in 100 women who deliver vaginally (4).

None of this is inevitable. The question is what can be done about it, starting now.

Paid subscribers can access the full instructions:

PAYWALL BREAK | Free readers see above. Paid subscribers continue below.

Read more

The message: “Defending reproductive health care means defending access to mifepristone.”

Your first question, entirely reasonable, entirely innocent: what is reproductive health care?

Here is what the term actually covers.

Reproductive health care is the full range of medical services related to the human reproductive system. Prenatal care. Labor and delivery. Postpartum recovery. Contraception. Fertility treatment. Miscarriage management. Ectopic pregnancy treatment. Abortion. Cervical and ovarian cancer screening. STI testing and treatment. Menopause management. Pelvic floor disorders.

It is most of what an obstetrician-gynecologist does across a patient’s entire life.

So your second question, still innocent, still reasonable: does all of that depend on one specific medication? Mifepristone?

The answer is no.

Subscribe now

The alien has just found the problem.

Prenatal care does not depend on mifepristone. Fertility treatment does not depend on mifepristone. Cervical cancer screening does not depend on mifepristone. Mifepristone is used for medical abortion and miscarriage management. It is one drug within a very large category.

You identified that in about 90 seconds.

American organized medicine has avoided it for 25 years.

ACOG uses the phrase. ACOG does not define it.

Search ACOG’s website. You will find “reproductive health care” in hundreds of statements, position papers, and press releases. You will not find a formal clinical definition with boundaries.

ACOG’s stated position is that abortion is an essential component of comprehensive medical care and that patients need access to the full spectrum of reproductive health care options. The “full spectrum” is invoked constantly. It is never mapped.

A professional organization that sets evidence standards for an entire specialty should be able to define its own operating terms.

Why this matters beyond semantics.

When “reproductive health care” is used as a rhetorical container rather than a clinical category, it does two things simultaneously.

Subscribe now

It signals, appropriately, that the term covers far more than any single procedure or medication.

And it allows any single element within that undefined category to carry the full moral and political weight of the entire category.

Every patient who has ever received prenatal care, an IUD, or a Pap smear is implicitly recruited into the defense of one specific drug. That may be effective advocacy. It is not precise medicine.

The mifepristone case stands on its own evidence.

Mifepristone has a well-established safety record. The FDA approved it in 2000. Decades of post-marketing data confirm that profile. The case for protecting access is strong.

Make that case. Lead with the safety data. Lead with what happens to patients when access is restricted.

The evidence is strong enough to stand without an undefined umbrella term doing the heavy lifting.

While we are talking about access: where is the Digital Day of Action for equal access to an OB-GYN?

Here is the alien’s third question, still innocent, still devastating: if ACOG can mobilize a national day of action to protect one medication, why has there been no Digital Day of Action to ensure that every woman in America, regardless of insurance status or race, has equal access to an obstetrician-gynecologist?

The data are not ambiguous.

The numbers.

OB-GYNs accept new Medicaid patients at a rate of 81.7%. They accept new privately insured patients at 98.9%. That 17-point gap represents millions of women who cannot get an appointment at the same practice a commercially insured woman can call tomorrow.

Medicaid covers more than 4 in 10 births in the United States. It covers 65% of all births to Black mothers. It covers 30% of Black reproductive-age women and 26% of Hispanic reproductive-age women, compared to 20% of reproductive-age women overall.

The arithmetic is straightforward. Insurance discrimination in OB-GYN access is racial discrimination in OB-GYN access. The two cannot be separated.

Where Medicaid patients actually go.

Private OB-GYN practices accept Medicaid at 77%. Community health centers accept Medicaid at 90%. As a result, nearly half of Medicaid patients receive OB-GYN care at community health centers, while only about one in four patients at private practices is on Medicaid.

The system has sorted women into a two-tier architecture: privately insured women see private physicians; Medicaid patients go to clinics. ACOG members built that architecture. Approximately one-third of ACOG members have made changes to their practices specifically to limit or eliminate Medicaid patients.

This is not an accusation. It is what the survey data show.

The consequences are not hypothetical.

Black women die from pregnancy-related causes at more than 3 times the rate of white women. Severe maternal morbidity is 2.1 times higher for Black women than for white women. These gaps do not exist in a vacuum. They exist in a system where the women at highest risk are the most likely to be denied access to a private OB-GYN practice.

Defending reproductive health care, if that phrase means anything, means defending equal access to the full category of care it supposedly describes. For every woman. At every practice. Regardless of what card she hands to the front desk.

The question ACOG has not answered.

Why does a Digital Day of Action exist for one medication used primarily by insured patients who can access a physician, but not for the structural barrier that prevents the most vulnerable women from accessing any obstetrician at all?

Mifepristone access and equal Medicaid access are not competing issues. Both matter. Both deserve mobilization.

The alien noticed the asymmetry immediately.

What I am asking for is consistency.

Define reproductive health care. Then defend all of it. For all women.

That is what evidence-based advocacy looks like.

The alien figured out both problems in about 90 seconds. We can do better.

#ObGynIntelligence #ReproductiveHealth #HealthEquity #Medicaid #MaternalHealth #ACOG #WomensHealth

A low ferritin level during pregnancy is not a laboratory curiosity. It is a clinical problem with a trajectory. Ferritin measures stored iron. When stores fall, the body begins borrowing from itself: first from the liver, then from muscle, then from red cell precursors.

By the time hemoglobin drops below 11 g/dL, iron deficiency has already been present for weeks or months. Waiting for that threshold to treat is not watchful waiting. It is delayed care.

The question is no longer whether iron deficiency in pregnancy matters.

It does.

The questions are who qualifies for IV iron, when, and why access remains so difficult even when the clinical picture is unambiguous.

What Iron Deficiency Actually Does in Pregnancy

Iron requirements increase roughly six-fold during pregnancy, from approximately 1 mg per day outside of pregnancy to 6 mg per day in the third trimester (1). Oral supplementation addresses part of this demand but is limited by absorption, tolerance, and compliance. The gut absorbs a fraction of what is swallowed, and side effects from oral iron, including nausea, constipation, and abdominal pain, lead many women to take it inconsistently or stop entirely.

Iron deficiency anemia affects an estimated 38% of pregnant women worldwide (2).

In the United States, Black and low-income women are disproportionately affected, a disparity driven by baseline dietary access and unequal access to prenatal care (3).

But the burden extends well beyond official anemia statistics. Iron depletion without anemia, meaning low ferritin with a still-normal hemoglobin, is not captured in those numbers.

The downstream consequences are documented.

Maternal anemia increases the risk of postpartum hemorrhage through impaired uterine contractility (4). Low postpartum iron stores are associated with a two- to four-fold increase in the odds of postpartum depression across multiple studies (5). Postpartum anemia has also been linked to impaired cognition, early cessation of breastfeeding, and fatigue severe enough to interfere with infant care (6). Neonatal iron stores depend on maternal iron status in the third trimester, when the majority of fetal iron transfer occurs (1). A depleted mother is more likely to deliver a neonate with depleted stores.

These are not speculative associations. They are consistent findings across observational data, and they argue for treating iron deficiency before hemoglobin collapses, not after.

The Evidence for IV Iron

ACOG Practice Bulletin Number 233 (2021) defines anemia in pregnancy as a hemoglobin below 11 g/dL in the first and third trimesters and below 10.5 g/dL in the second trimester (7). It recommends oral iron as first-line treatment and acknowledges IV iron as safe and effective for patients who do not respond to oral therapy, cannot tolerate it, or require rapid iron repletion. That threshold requirement, oral iron failure, is where the access problem begins.

Subscribe now

A 2024 meta-analysis including six studies and 3,842 participants found that IV iron produced significantly higher hemoglobin compared to oral iron, with a pooled mean difference of 1.21 g/dL (95% CI 0.83 to 1.59), and was more than twice as likely to correct anemia (OR 2.47; 95% CI 1.69 to 3.61) (8). The efficacy advantage of IV iron over oral iron is not a fringe finding. It is replicated across randomized controlled trials and meta-analyses.

The safety concern most often cited is hypersensitivity. That concern is outdated in its severity framing. Older dextran-based formulations carried real anaphylaxis risk. Modern formulations do not. For ferric carboxymaltose, the adjusted anaphylaxis rate in Medicare data is 0.8 per 10,000 first doses (9). Serious reactions are rare, and they occur in settings already equipped to manage them. A 30-minute infusion with 30 minutes of monitoring does not require intensive care capacity. It requires a chair, a line, and a nurse familiar with the protocol.

Ferric carboxymaltose permits single-dose administration of up to 1,000 mg in a 15-minute infusion with a well-characterized safety profile across more than 8,000 subjects in clinical studies (10). The argument that IV iron is too risky for routine use in pregnancy is not supported by the pharmacovigilance data on modern formulations.

The rest of this post is for paid subscribers.

Read more

She was 34, first pregnancy, no complications. The birth went smoothly by every metric in her chart. Apgar scores 9 and 9. Three hours of pushing, but vaginal delivery. Baby healthy. Mother discharged in good condition.

Six weeks later she sat in my office and told me she could not sleep, could not be touched, and had nightmares about the delivery every …

Read more

Tennessee has a maternal mortality rate of 41 per 100,000 live births.

California’s is 10.

Mississippi’s neonatal mortality rate is 5.3 per 1,000 live births.

Vermont’s is 2.1.

These are not random numbers. Two datasets, drawn from CDC/NCHS vital statistics and America’s Health Rankings analyses of CDC WONDER, show the same pattern: states with higher Republican presidential vote shares in 2020 have substantially worse maternal and neonatal mortality.

The maternal mortality correlation coefficient is 0.57. For neonatal mortality, it is 0.43. Both charts note explicitly that these are ecological associations, not causal ones. That disclaimer matters, and I will return to it. But a correlation coefficient of 0.57 is not noise. It is a signal that demands explanation.

Subscribe now

What the Data Actually Show

The maternal mortality scatter plot covers 2018 to 2022, using CDC/NCHS state-level rates. The neonatal mortality plot covers 2022 to 2023 from America’s Health Rankings. Both use 2020 presidential vote share as the X-axis. In both charts, the fitted regression line runs upward left to right: states with lower Republican vote shares cluster toward the bottom, states with higher vote shares cluster toward the top.

The outliers are instructive. Utah votes heavily Republican and has a maternal mortality rate around 15.5 per 100,000 -- well below the trend line.

West Virginia sits high-Trump and relatively moderate on maternal mortality compared to Mississippi or Tennessee.

Delaware, a blue state, has a neonatal mortality rate near 4.9. No correlation in population-level data is clean.

What matters is the pattern across dozens of states, not any single data point.

The pattern is real. In states that voted more than 60% for Trump in 2020, maternal mortality consistently runs above 37 per 100,000 live births. In states below 35% Trump share, it runs closer to 10 to 13. That is a three-to-four-fold difference in the rate at which women die from pregnancy-related causes, depending on which state they live in.

Correlation Is Not Causation -- But the Mechanisms Are Not a Mystery

This matters: voting Republican does not cause maternal death. The ecological fallacy reminds us that state-level associations do not translate to individual-level causation. A state’s average vote share and its average mortality rate are population-level statistics, and we cannot infer that any individual voter is at elevated risk because of her politics.

Subscribe now

What we can ask is why these two variables track together at the state level. And here the answer is not mysterious. It is healthcare policy. The states that vote most heavily Republican are, with notable exceptions, the same states that rejected Medicaid expansion under the Affordable Care Act, that have the fewest OB/GYN physicians per capita, that have enacted the most restrictive abortion laws (which have well-documented downstream effects on obstetric care capacity and physician recruitment), and that have the highest proportions of rural counties without a labor and delivery unit.

Medicaid finances 41% of all births in the United States nationwide. In Louisiana, Mississippi, New Mexico, and Oklahoma, more than half of all births are Medicaid-financed. These states are also among the highest on both mortality curves. Medicaid is not a peripheral program for maternal health. It is the program. Remove it or restrict it, and you are removing the financial infrastructure that keeps maternity care functioning in the communities where it is most needed.

Share

There is also the abortion care dimension, which clinicians are not permitted to ignore. Since 2022, multiple states have enacted near-total abortion bans. The evidence is accumulating that these laws reduce the obstetric workforce, deter medical students from training in affected states, and create clinical paralysis when physicians face pregnancy complications that technically qualify as emergencies but carry legal risk. Maternal mortality in states with abortion bans is a topic that requires its own post. But anyone reading these scatter plots should understand that the political and clinical environments are not separate.

What the Federal Budget Just Did to These States

On July 4, 2025, the One Big Beautiful Bill Act was signed into law. The legislation cuts federal Medicaid funding by approximately $1 trillion, or roughly 15%, over ten years. The nonpartisan Congressional Budget Office estimates that 11.8 million individuals will directly lose Medicaid health insurance coverage as a result, with an additional 3.1 million losing Medicaid coverage under marketplace plans.

The states that are highest on both mortality scatter plots are the states where Medicaid coverage of births is most concentrated. Families USA estimates that more than half of births in Louisiana, Mississippi, and Oklahoma are financed by Medicaid. The National Partnership for Women and Families has estimated that more than 140 labor and delivery units will close under the cuts. The National Rural Health Association projects rural hospitals will face as much as $70 billion in reduced funding. These are not distant projections -- they describe what happens to the clinical infrastructure of the states already sitting in the upper-right quadrant of both graphs.

The law also introduces new administrative work requirements for Medicaid eligibility, which the Commonwealth Fund and multiple maternal health organizations have identified as creating particular risk for women of reproductive age who are not employed for pay due to childcare, illness, or school attendance. Consistent coverage before, during, and after pregnancy is not optional -- it is how preventable maternal deaths get prevented. Gaps in coverage during pregnancy are associated with delayed prenatal care, unmanaged chronic conditions, and worse outcomes at delivery. Forty-eight states had extended postpartum Medicaid coverage to 12 months. The cuts put that extension at serious risk as states face budget shortfalls they did not choose.

What Patients Should Know

If you live in a state with a maternal mortality rate above 30 per 100,000 live births -- Tennessee, Mississippi, Louisiana, Georgia, Kentucky among them -- you should know that the risk difference between your state and a lower-mortality state is not explained just by biology or by the complexity of your pregnancy.

It is explained largely by the healthcare system around you: how many OB/GYNs practice in your county, whether the nearest hospital has a labor and delivery unit, whether your insurance covers your prenatal visits without administrative barriers.

Medicaid is not a safety net program for someone else.

It is the program that financed your neighbor’s delivery, your county’s only OB, and potentially your own postpartum care. When 11.8 million people lose Medicaid coverage, the effects do not stay within that group. They ripple through clinics and hospitals that serve mixed-payer populations and that may no longer be financially viable when a substantial share of their revenue disappears.

Ask your state legislators whether they plan to maintain the 12-month postpartum Medicaid extension. Ask your congressional representatives how they voted on the One Big Beautiful Bill Act. These are not abstract policy questions. They are questions about whether the labor and delivery unit nearest you will still be open in three years.

My Take

I have been practicing obstetrics for more than 50 years. I have watched maternal mortality statistics be debated, dismissed, recalculated, and reframed. What I know from that experience is this: a maternal mortality rate of 41 per 100,000 in Tennessee and 10 per 100,000 in California does not reflect a difference in how sick or complex those patients are.

It reflects a difference in resources. Period.

The scatter plots circulating in health policy circles are not partisan attack documents. They are descriptive epidemiology with an honest methodological caveat -- ecological association, not individual causation -- printed right on the chart. The researchers who produced them were transparent. The correlation is real, the mechanisms are identifiable, and the policy response is now law.

The states where mothers are most likely to die from pregnancy-related causes will absorb cuts to the very program that finances those mothers’ care. The states where neonatal mortality is highest will lose labor and delivery units in rural counties that already have too few. We are not predicting a possible future outcome. We are describing the predictable consequence of cutting $1 trillion from Medicaid in a country where Medicaid is the largest single payer for childbirth.

These two scatter plots show a correlation. The federal budget signed on July 4 is about to run a natural experiment on whether that correlation can be made worse.

My prediction: yes, it can.

If you are a free subscriber and you found this useful, a paid subscription supports independent, evidence-based coverage of the questions in women’s health that the major professional societies too often leave unanswered.

References

1. CDC/NCHS. Maternal deaths and mortality rates by state, 2018-2022. National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/ [As shown in graph source line; individual state-level report citation to be confirmed -- VERIFY DOI/URL]

2. America’s Health Rankings. Analysis of CDC/NCHS linked birth/infant death records via CDC WONDER, 2022-2023. United Health Foundation. Available from: https://www.americashealthrankings.org [VERIFY current URL]

3. Joyce D, Marceno L, Eisen H. Medicaid cuts could increase maternal mortality and jeopardize women’s health. Commonwealth Fund; May 2025. Available from: https://www.commonwealthfund.org/blog/2025/medicaid-cuts-could-increase-maternal-mortality-and-jeopardize-womens-health

4. Guttmacher Institute. New federal Medicaid cuts will devastate coverage for reproductive health care; November 2025. Available from: https://www.guttmacher.org/2025/11/new-federal-medicaid-cuts-will-devastate-coverage-reproductive-health-care

5. Georgetown University Center for Children and Families. Pregnant women, infants, young children are not protected in proposed Medicaid cuts; July 2025. Available from: https://ccf.georgetown.edu/2025/07/01/worth-repeating-pregnant-women-infants-young-children-are-not-protected-in-proposed-medicaid-cuts/

6. National Partnership for Women and Families. At risk: critical Medicaid benefits for moms; April 2025. Available from: https://nationalpartnership.org/report/at-risk-critical-medicaid-benefits-for-moms/

7. Congressional Budget Office. Estimated budgetary effects of H.R.1, One Big Beautiful Bill Act; 2025. [VERIFY final CBO report citation and DOI]

8. Families USA. The biggest threats to maternal health lurking in President Trump’s health care cuts; September 2025. Available from: https://familiesusa.org/resources/the-biggest-threats-to-maternal-health-lurking-in-president-trumps-health-care-cuts/

A malpractice case lands on your desk. Actually it was slipped under your door. The envelope sits there before you open it, and for a moment, everything you have built, your training, your decisions, your identity as a clinician, feels like it is on trial.

That feeling is understandable.

It is also, I would argue, the wrong frame entirely.

The next step is to let your lawyer and/or the hospital’s lawyer know about it.

A wise attending once told me to take the rest of the day off when you received a letter you have beed sued as you are now “incompetent” and upset.

I wrote recently about why ObGyns and their departments should approach malpractice differently, not as a catastrophe to survive, but as a case to read.

An attorney who works these cases from the other side of the table responded with something that stopped me.

He wrote that adverse outcomes and litigation do not just test clinicians; they can sharpen judgment, deepen empathy, and reinforce the importance of communication and documentation.

He called it how professionals often refine both technical skills and the ability to navigate risk, uncertainty, and patient expectations.

When the person whose job it is to hold you accountable says this, it is worth paying attention.

What a Lawsuit Actually Is

A malpractice case is a data point. But before the family or their attorney decided something went wrong, something already did go wrong. The first requirement for any malpractice claim is damage — a bad outcome, a genuine adverse event, a patient or newborn who was harmed. That is where every case starts, not with a legal theory but with a real injury. Without damage, there is no claim, no matter how many mistakes were made.

Read more

She is 34 years old. She has a graduate degree. She has private health insurance. She is Black. And according to the published data, her risk of dying from a pregnancy-related cause is comparable to that of a white woman living below the poverty line.

This is not a metaphor. It is a finding from population-level research. And it is the single most important data point in the maternal mortality debate that never receives the attention it deserves, because it is deeply inconvenient for the dominant narrative.

The dominant narrative goes like this: Black women die at three to four times the rate of white women in childbirth, and the cause is racism. Implicit bias in clinicians. Structural racism in society. Historical medical trauma. Chronic stress from discrimination. Fix the racism, fix the mortality.

I have spent 50 years in obstetrics. I do not doubt that racism exists in clinical settings. I have seen it. I have worked to address it. But I have come to believe, based on the evidence, that the solutions being deployed in the name of racial equity in maternal health are largely aimed at the wrong target. They are addressing attitudes while the structure does the killing. And that distinction matters enormously, because structural problems have structural solutions, while attitude problems are extraordinarily difficult to measure, modify, or hold accountable.

Subscribe now

This series examines the evidence. All of it. Including the parts that make the mainstream conversation uncomfortable.

The Number

The mortality ratio is not disputed. In the United States, Black women die from pregnancy-related causes at approximately three to four times the rate of non-Hispanic white women. The Centers for Disease Control and Prevention reported a pregnancy-related mortality ratio of 69.9 per 100,000 live births for Black women in 2021, compared with 26.6 per 100,000 for white women. These are not statistical artifacts. They represent real deaths, real families, real failures of a medical system that is demonstrably not serving all patients equally.

The question is not whether the gap exists. It does. The question is what drives it. And the answer to that question determines what interventions could plausibly close it.

The Income Data That Changes the Argument

In 2022, researchers at Stanford published an analysis of maternal and infant health outcomes stratified by income. The findings deserve to be read carefully, because they disrupt several comfortable assumptions simultaneously.

Among the key findings: babies born to Black mothers in the top 5 percent of the income distribution are one and a half times more likely to be preterm and of low birthweight than infants born to white mothers in the bottom 5 percent of the income distribution. Read that again. The wealthiest Black mothers, producing children who are materially privileged from the first breath, have worse birth outcomes than the poorest white mothers. High-income Black mothers face the same risk of dying in the first year following childbirth as the poorest white mothers.

Subscribe now

If poverty were the primary driver of the disparity, this finding would not exist. Wealth protects white women from bad outcomes. It does not protect Black women to the same degree. Something else is operating, and it operates across income levels.

This finding has profound implications for policy. It means that income transfers, educational interventions, and poverty reduction programs, while important for many reasons, should not be expected to close the racial maternal mortality gap. The structural mechanism causing excess deaths among Black women is not poverty alone. It is something embedded in the system of care delivery that persists even when individual economic barriers are removed.

What the Evidence Points Toward

When a disparity survives income adjustment, researchers look for what else is distributed unequally across race even among high-income individuals. The candidates are:

First, where women deliver. Hospital quality is not distributed randomly across race. A simulation analysis found that if Black mothers delivered at the same hospitals as white mothers, the Black maternal morbidity rate would decrease by 47.7 percent. This is not a small effect. This is nearly half the excess burden, addressable by changing which building a woman walks into when she begins labor, without changing any individual clinician’s attitudes or behaviors.

Second, what kind of prenatal care women receive before they ever walk into a delivery room. Access to continuous prenatal care from the same provider, access to faculty-level obstetric care in academic settings, access to timely specialist consultation. These are not uniformly available across insurance types. And insurance type is distributed along racial lines in ways that persist even among women who are not in poverty.

Share

Third, the structure of the postpartum period. More than half of all pregnancy-related deaths in the United States occur after delivery. Among those, a significant proportion occur after the 60-day postpartum window during which Medicaid historically covered care. A woman who delivers safely can lose her coverage, lose her follow-up care, and die of a cardiovascular complication weeks later that was entirely preventable if anyone had seen her.

These are structural problems. They have structural solutions. They do not require waiting for racism to disappear from human hearts. They require policy changes, payment changes, and institutional accountability.

What the Evidence Does Not Clearly Show

It is worth being precise about what the evidence does and does not establish, because the conversation around Black maternal mortality has become susceptible to a particular form of intellectual slippage: the assumption that because racism causes other bad outcomes, racism must be the primary driver of this one.

A systematic review searching 2,394 studies examining the quantitative link between structural racism measures and maternal morbidity and mortality found that only 6 studies met the inclusion criteria for rigorous analysis. Six. From 2,394. The results of those six studies were heterogeneous, meaning they did not all point in the same direction, and the authors concluded that the evidence base required substantial methodological development before definitive conclusions could be drawn.

This does not mean structural racism does not affect maternal health. It means the evidentiary basis for the specific causal claim is far weaker than the confidence with which it is stated in most public health discourse. That gap between claim and evidence is a clinical problem, because interventions built on unverified causal models will not produce the expected results, and patients will continue to die while policymakers congratulate themselves on having addressed the right problem.

The Series Ahead

Over the next nine posts, this series will examine the specific structural mechanisms that the evidence points toward as drivers of the Black maternal mortality disparity. We will look at the insurance payment hierarchy that determines which patients get faculty care and which get residents. We will look at the academic medical institutions that publish on maternal health disparities while operating two-tier practice systems. We will look at the hospital quality data that shows where you deliver matters more than almost any other single variable. We will look at the evidence, or lack of it, behind the interventions that have been deployed most enthusiastically: implicit bias training and doula care.

And we will ask the question that the mainstream conversation consistently avoids: if the structural mechanisms driving Black maternal mortality are well understood, and the structural solutions are available, who benefits from keeping the focus on attitudes rather than systems?

The three-times number is real. The deaths behind it are real. What has not been real, in much of the policy response, is the connection between the proposed interventions and the actual mechanisms of harm. That disconnect is what this series is about.

My Take

I began my career in obstetrics in 1974. I have watched this field evolve through sonography, through the cesarean epidemic, through evidence-based medicine, through the ARRIVE trial, through the rise of social media misinformation, and through the arrival of large language models. I have seen many ideas celebrated before the evidence arrived and discarded after it did.

The current framework for addressing Black maternal mortality follows a familiar pattern. The disparity is real. The moral urgency is genuine. But the interventions being deployed, mandatory implicit bias training, doula programs with minimal regulatory oversight and no demonstrated mortality benefit, have been adopted with the speed and confidence of a field that has already decided on the answer and is selectively reading the evidence to support it.

I am not arguing that racism is irrelevant to this problem. I am arguing that a medical specialty that builds interventions on causal models that have not been rigorously tested is not practicing evidence-based medicine. It is practicing evidence-adjacent medicine, which looks like science from a distance and does not save lives up close.

The income data from Stanford should have reoriented this conversation two years ago. It did not, because it points toward structural solutions that are harder and more expensive than bias training. Raising Medicaid reimbursement rates costs money. Requiring faculty practices to accept Medicaid patients costs political capital. Holding academic medical centers accountable for their two-tier systems requires naming institutions that hold endowed chairs in health equity.

That is the work this series is asking for. Not the abandonment of the racial equity framework, but its honest application to the mechanisms that the evidence actually supports.

This series runs to ten posts. Posts 4 through 10, covering hospital quality, maternity care deserts, the implicit bias evidence, the doula data, the postpartum coverage cliff, and the closing argument on who benefits from the current policy response, are available to paid subscribers at obmd.com. Annual subscription: $60.

References

1. Centers for Disease Control and Prevention. Maternal Mortality Rates in the United States, 2021. NCHS Data Brief No. 469. Hyattsville, MD: National Center for Health Statistics; 2023.

2. Persson P, Rossin-Slater M. Family Ruptures, Stress, and the Mental Health of the Next Generation. Stanford Institute for Economic Policy Research Working Paper; 2022. [Stanford/SIEPR income-stratified maternal outcomes analysis].

3. Howell EA, Brown H, Brumfield C, et al. Reduction in Preterm Births at High-Volume Hospitals: Do Racial Disparities Disappear? Am J Obstet Gynecol. 2016;214(5):640.e1-640.e7.

4. Tangel V, White RS, Nachamie AS, Pick JS. Racial and Ethnic Disparities in Maternal Outcomes and the Disadvantage of Peripartum Black Women: A Multistate Analysis, 2007-2014. Am J Perinatol. 2019;36(8):835-848.

5. Crear-Perry J, Correa-de-Araujo R, Lewis Johnson T, McLemore MR, Neilson E, Wallace M. Social and Structural Determinants of Health Inequities in Maternal Health. J Womens Health (Larchmt). 2021;30(2):230-235.

6. Wallace ME, Mendola P, Liu D, Grantz KL. Joint Effects of Structural Racism and Income Inequality on Small-for-Gestational-Age Birth. Am J Public Health. 2015;105(8):1681-1688.

7. Njoku A, Evans M, Nimo-Sefah L, Bailey J. Listen to the Whispers Before They Become Screams: Addressing Black Maternal Morbidity and Mortality in the United States. Healthcare (Basel). 2023;11(3):438.